thalidomide has been researched along with apremilast in 545 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (0.73) | 29.6817 |
| 2010's | 278 (51.01) | 24.3611 |
| 2020's | 263 (48.26) | 2.80 |
| Authors | Studies |
|---|---|
| Dredge, K | 1 |
| Braddock, M; Murray, C | 1 |
| Gottlieb, AB; Hu, CC; Kipnis, C; Krueger, JG; Rohane, P; Strober, B; Zeldis, JB | 1 |
| Babusis, DM; Blease, K; Chen, R; Corral, LG; Leisten, J; Man, HW; Muller, GW; Patterson, RT; Raymon, H; Schafer, P; Shirley, MA; Stirling, D; Tang, Y; Wong, LM | 1 |
| Adams, M; Baillie, GS; Bartlett, JB; Capone, L; Cheung, YF; Gandhi, AK; Gilhar, A; Houslay, MD; Loveland, MA; Man, HW; Muller, GW; Parton, A; Schafer, PH; Stirling, DI; Wu, L | 1 |
| Andrews, M; Brennan, FM; Feldmann, M; Inglis, JJ; McCann, FE; Palfreeman, AC; Perocheau, DP; Schafer, P; Williams, RO | 1 |
| Capone, L; Cedzik, D; Feng, H; Fong, KL; Gu, Z; Heller, D; Hoffmann, M; Kumar, G; Laskin, O; Schafer, P; Surapaneni, S; Wu, A | 1 |
| Baughman, RP; Craft, NL; Ingledue, R; Judson, MA; Lower, EE | 1 |
| Schafer, P | 1 |
| Au, SC; Dumont, N; Gottlieb, AB; Scheinman, P; Volf, EM | 1 |
| Del Pino-Montes, J; Gómez-Castro, S; Hidalgo, C; López, R; Montilla Morales, C; Sánchez, M | 1 |
| Berry, TM; Goreshi, R; Samrao, A; Simpson, EL | 1 |
| Feldman, S; Pellerin, M; Shutty, B; West, C | 1 |
| Cather, JC; Day, RM; Hu, C; Langley, RG; Matheson, RT; Papp, K; Rosoph, L; Sofen, H | 1 |
| van de Kerkhof, PC | 1 |
| de Vlam, KL; Hu, C; Joos, R; Papp, K; Rodrigues, JF; Schett, G; Stevens, R; Vessey, AR; Wollenhaupt, J | 1 |
| Cunningham, TD; Foss, CE; Hirano, SA; Pariser, DM; Paul, J | 1 |
| Abraham, S; Charles, PJ; Chowdhury, M; Keat, A; McClinton, C; Paterson, E; Pathan, E; Taylor, PC; Van Rossen, E; Withrington, R | 1 |
| Hu, C; Kaufmann, R; Papp, KA; Rohane, P; Sutherland, D; Thaçi, D | 1 |
| De Souza, A; Franks, AG; Merola, JF; Oliver, S; Strober, BE | 1 |
| Crow, JM | 1 |
| Goldminz, AM; Gottlieb, AB; Kim, N; Kumar, N | 1 |
| McCann, FE; McNamee, KE; Palfreeman, AC | 1 |
| Hu, C; Schett, G; Stevens, RM; Strand, V | 1 |
| Harrison, C | 1 |
| Gavaldà, A; Roberts, RS | 1 |
| Day, RM; Fiorentino, D; Hu, C; Papp, KA; Stevens, RM; Strand, V | 1 |
| Day, RM; Gottlieb, AB; Hu, C; Krueger, JG; Leonardi, CL; Matheson, RT; Menter, A; Schafer, PH | 1 |
| Adebajo, AO; Gladman, DD; Gomez-Reino, JJ; Hall, S; Hochfeld, M; Hough, D; Hu, C; Kavanaugh, A; Lespessailles, E; Mease, PJ; Schett, G; Stevens, RM; Wollenhaupt, J | 1 |
| Fraser, K | 1 |
| Gottlieb, AB; Tintle, SJ; Varada, S | 1 |
| Ballantyne, AD; Poole, RM | 1 |
| FitzGerald, O | 1 |
| Feldman, SR; Moustafa, F | 1 |
| Brady, H; Capone, L; Cedzik, D; Chopra, R; Evans, JF; Man, HW; Muller, GW; Parton, A; Schafer, PH; Stirling, DI | 1 |
| Ratner, M | 1 |
| Liu, Y; Palmisano, M; Wan, Y; Wu, A; Zhou, S | 1 |
| Song, SD; Tang, HF | 1 |
| Morrow, T | 1 |
| Hansen, RB; Kavanaugh, A | 1 |
| Chakraborty, B; Furniss, M; Mackay-Wiggan, J; Thompson, BJ; Zhao, W | 1 |
| Krause, A; Märker-Hermann, E | 1 |
| Leonardi, CL; Sobell, JM | 1 |
| Sigler, J | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Gottlieb, AB; Tintle, SJ | 1 |
| Atzeni, F; Sarzi-Puttini, P | 1 |
| Gilhar, A; Keren, A; Paus, R; Shemer, A; Ullmann, Y | 1 |
| Adebajo, AO; Gladman, DD; Gomez-Reino, JJ; Hall, S; Hochfeld, M; Kavanaugh, A; Lespessailles, E; Mease, PJ; Schett, G; Teng, LL; Wollenhaupt, J | 1 |
| Felquer, ML; Soriano, ER | 1 |
| Mahmood, T; Menter, A; Zaghi, D | 1 |
| Hussar, DA | 1 |
| Alper, J; Chen, M; Cieślak, D; Genovese, MC; Hough, DR; Jarosova, K; Kivitz, A; Maes, P; Pineda, L; Zaidi, F | 1 |
| Busa, S; Kavanaugh, A | 1 |
| Goldenberg, G; Mansouri, Y | 1 |
| Abdulrahim, H; Adebajo, AO; Edwards, C; Shaw, T; Thistleton, S; Wells, A | 1 |
| Calamia, KT; Hatemi, G; Korkmaz, C; Liu, Z; Mat, C; Melikoglu, M; Merkel, PA; Pineda, L; Stevens, RM; Tunc, R; Turgut Ozturk, B; Yazici, H; Yazici, Y | 1 |
| Chen, P; Chopra, R; Fang, L; Schafer, PH; Wang, A | 1 |
| Robinson, AN; Scully, C | 1 |
| Chimenti, S; Day, RM; Gordon, KB; Griffiths, CE; Hu, C; Kircik, L; Korman, NJ; Langley, RG; Leonardi, CL; Papp, K; Reich, K; Stevens, RM | 1 |
| Beroukhim, K; Danesh, MJ; Koo, J; Levin, E; Nguyen, C | 1 |
| Deeks, ED | 2 |
| Bianchi, L; Buonomo, O; Chimenti, MS; Chimenti, S; Chiricozzi, A; Garofalo, V; Gramiccia, T; Perricone, R; Saraceno, R | 1 |
| Koo, J; Levin, E; McAndrew, R | 1 |
| Klufas, DM; Strober, BE; Wald, JM | 1 |
| Cather, J; Crowley, J; Day, RM; Ferrandiz, C; Girolomoni, G; Gooderham, M; Gottlieb, AB; Hu, C; Mrowietz, U; Paul, C; Poulin, Y; Shah, K; Stevens, RM | 1 |
| Cronstein, B; Mediero, A; Montesinos, MC; Perez-Aso, M; Schafer, PH; Wilder, T | 1 |
| Corr, M; Kehl, AS; Weisman, MH | 1 |
| Soriano, ER | 1 |
| Gooderham, M; Papp, K | 1 |
| Gómez-Reino, JJ; Souto, A | 1 |
| Cavanaugh, K; Curiel-Lewandrowski, C; Krase, IZ | 1 |
| Notaro, ER; Sidbury, R | 1 |
| Bachelez, H; Chen, R; Crowley, J; Day, RM; Goncalves, J; Gooderham, M; Rich, P | 1 |
| Cannizzaro, MV; Caposiena, D; Chimenti, S; Chiricozzi, A; Garofalo, V; Saraceno, R | 1 |
| Aldredge, L; Armstrong, AW; Yamauchi, PS | 1 |
| Betts, KA; Friedman, A; Ganguli, A; Griffith, J; Signorovitch, JE; Zhou, ZY | 1 |
| Bank, M; Haber, SL; Hamilton, S; Leong, SY; Pierce, E | 1 |
| Aelion, J; Birbara, CA; Bird, P; Blanco, FJ; Crowley, J; Edwards, CJ; Jaworski, J; Stevens, RM; Vessey, A; Zhan, X | 1 |
| D'Angelo, S; Olivieri, I | 1 |
| Horan, G; Kosek, J; Lotti, R; Marconi, A; Parton, A; Pincelli, C; Quadri, M; Saltari, A; Schafer, PH; Truzzi, F; Wu, L; Zhang, LH | 1 |
| Hinde, S; Palmer, S; Spackman, E; Wade, R; Woolacott, N | 1 |
| Chen, R; Day, RM; Foley, P; Girolomoni, G; Goncalves, J; Mrowietz, U; Sobell, JM; Toth, D; Yosipovitch, G | 1 |
| AbuHilal, M; Shear, N; Walsh, S | 1 |
| Qu, X; Song, Y; Tao, L; Zhang, S | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Beroukhim, K; Danesh, M; Koo, J; Leon, A; Nguyen, CM; Wu, JJ | 1 |
| Bissonnette, R; Chen, R; Day, RM; Goncalves, J; Pariser, DM; Sebastian, M; Wasel, NR | 1 |
| Chen, LG; Lai, X; Li, T; Pan, Y; Wang, S; Wang, Z | 1 |
| Goldminz, AM; Gottlieb, AB; Greb, JE; McQuade, B; Rothstein, BE | 1 |
| Bojke, L; Corbett, M; Palmer, S; Sideris, E; Woolacott, N | 1 |
| Assaf, M; Liu, L; Liu, Y; Palmisano, M; Park, CH; Savant, I; Wu, A; Zhou, S | 1 |
| Girolomoni, G; Gisondi, P | 1 |
| Anliker, M; Boehncke, WH; Borradori, L; Conrad, C; French, LE; Gilliet, M; Häusermann, P; Itin, P; Kolios, AG; Laffitte, E; Mainetti, C; Navarini, AA; Yawalkar, N | 1 |
| Bianchi, L; Chimenti, S; Chiricozzi, A; Del Duca, E; Romanelli, M; Saraceno, R | 1 |
| Cutolo, M; Díaz-González, F; Feist, E; Fleischmann, RM; Hu, C; Lioté, F; Marzo-Ortega, H; Myerson, GE; Poder, A; Shah, K; Stevens, RM; Van den Bosch, F | 1 |
| Armstrong, AW; Betts, KA; Signorovitch, JE; Sundaram, M; Thomason, D | 1 |
| Leonardi, CL | 1 |
| Bettencourt, M | 1 |
| Chen, R; Feldman, SR; Foley, P; Kimball, A; Levi, E; Poulin, Y; Thaçi, D | 1 |
| He, Y; Hu, P; Huang, S; Tang, M; Yu, H; Zheng, Q | 1 |
| Reich, A; Szepietowski, JC | 1 |
| Lubrano, E; Perrotta, FM | 1 |
| Bewley, A; Day, RM; Goncalves, J; Gooderham, M; Green, L; Khanskaya, I; Piguet, V; Reich, K; Shah, K; Soung, J; Zhang, Z | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Aljerian, K; Almukhlafi, TS; Almutairi, MM; Alshammari, M; Ansari, MA; Ansari, MN; Imam, F | 1 |
| Chandran, V; Maharaj, AB | 1 |
| Coates, LC; de Wit, M; Gossec, L; Kavanaugh, A; Mease, PJ; Ramiro, S; Ritchlin, CT; Smolen, JS; van der Heijde, D | 1 |
| Khemis, A; Lacour, JP; Montaudié, H; Passeron, T; Sfecci, A | 1 |
| Braun, J | 1 |
| Sieper, J | 1 |
| Roebuck, HL; Young, M | 1 |
| Assaf, M; Liu, Y; Nissel, J; Palmisano, M; Zhou, S | 1 |
| Bianchi, L; Dattola, A; Del Duca, E; Gramiccia, T; Saraceno, R | 1 |
| Bergmann, C; Beyer, C; Distler, JHW; Kittan, N; Maier, C; Ramming, A; Schett, G; Weinkam, R | 1 |
| Keating, GM | 1 |
| Schmutz, JL | 2 |
| Bueno-Rodriguez, A; Ruiz-Villaverde, R; Tercedor-Sánchez, J | 1 |
| Alikhan, A; Vangipuram, R | 1 |
| Bagel, J; Chen, R; Duffin, KC; Gottlieb, AB; Levi, E; Papp, KA | 1 |
| Croney, S | 1 |
| Chen, T; Geller, L; Levitt, J | 1 |
| Dann, FJ; Martin, BC; Thomas, LW | 1 |
| Alikhan, A; Flores, S; Loyal, J | 1 |
| Alanazi, FK; Alsarra, IA; Haq, N; Shakeel, F | 1 |
| Laumann, AE; Lee, D; Lund, E; Nardone, B; Orrell, KA; Rangel, SM; Vakharia, PP; West, DP | 1 |
| Chen, P; Day, RM; Imafuku, S; Komine, M; Maroli, A; Nemoto, O; Ohtsuki, M; Okubo, Y; Petric, R | 1 |
| Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D | 1 |
| Reddy, SP; Shah, VV; Wu, JJ | 1 |
| Hang, T; Lu, Y; Shen, X; Song, M | 1 |
| Döbel, T; Ebling, A; Enk, A; Kunze, A; Oehrl, S; Prakash, H; Schäkel, K; Schmitz, M; Trenkler, N; Wölbing, P | 1 |
| Hunger, RE; Seyed Jafari, SM; Weber, P; Yawalkar, N | 1 |
| Abrouk, M; Beroukhim, K; Bhutani, T; Farahnik, B; Koo, J; Lee, K; Liao, W; Nakamura, M; Singh, R; Zhu, TH | 1 |
| Bogdanos, DP; Mavropoulos, A; Sakkas, LI | 1 |
| Puig, L; Torres, T | 1 |
| D'Alessio, S; Danese, S; Peyrin-Biroulet, L; Spadaccini, M | 1 |
| Abrouk, M; Bhutani, T; Blossom, J; Farahnik, B; Koo, J; Lee, K; Liao, W; Lucking, SM; Nakamura, M; Nguyen, T; Shinkai, K; Singh, R; Zhu, TH | 1 |
| Fraser, C; Morton, CA; Sinclair, S; Smith, B; Wong, TH | 1 |
| Fink, C; Schäkel, K; Schank, TE; Trenkler, N; Uhlmann, L | 1 |
| Baillie, GS; Doi, K; Ishikura, S; Iwaihara, Y; Luo, H; Nishi, K; Sakata, T; Shirasawa, S; Tsunoda, T; Wills, L | 1 |
| Lee, YH; Song, GG | 2 |
| Bechtel, MA; Friedman, H; Gru, AA; Kaffenberger, BH; Kalik, JA | 1 |
| Bagel, J; Callis Duffin, K; Chen, R; Goncalves, J; Jackson, JM; Lebwohl, M; Levi, E; Stein Gold, L; Strober, B | 1 |
| Meyerle, J; Rosenberg, A | 1 |
| Afridi, F; Kar, P; King-Morris, K; Komarla, A; Perrone, D | 1 |
| Carter, J; Chawla, R; Persons, B | 1 |
| Barnetche, T; Brenaut, E; Misery, L; Théréné, C | 1 |
| Benigno, C; Bertolini, N; Caso, F; Caso, P; Chimenti, MS; Costa, L; Del Puente, A; Girolimetto, N; Peluso, R; Perricone, R; Sabbatino, V; Scarpa, R; Tasso, M | 1 |
| Dauden, E; de Jong, EM; Dressler, C; Feist, E; Gisondi, P; Jobling, R; Maccarone, M; Mrowietz, U; Nast, A; Ormerod, AD; Papp, KA; Paul, C; Reich, K; Rosumeck, S; Saiag, P; Smith, CH; Spuls, PI; Talme, T; Thio, HB; van de Kerkhof, P; van der Kraaij, G; Werner, RN | 1 |
| King, BA; Liu, LY | 1 |
| Herman, R; Monshi, B; Posch, C; Rappersberger, K; Richter, L; Sanlorenzo, M; Vujic, I | 1 |
| Dressler, C; Nast, A; Rosumeck, S; Spuls, P; van der Kraaij, G; van Lumig, P; Wakkee, M; Werner, RN | 1 |
| Baeten, DLP; van de Sande, MGH; van Mens, LJJ | 1 |
| Georgakopoulos, JR; Ighani, A; Shear, NH; Walsh, S; Yeung, J | 4 |
| Adamo, S; Cozzio, A; French, LE; Kolios, AGA; Krebs, A; Nilsson, J; Steiner, U | 1 |
| Bagel, J; Keegan, BR; Nelson, E | 1 |
| Greenberg, JD; Guo, N; Holmgren, SH; Karki, C; Lebwohl, M; Mason, M; Strober, B | 1 |
| Barber, K; Bissonnette, R; Bukhalo, M; Delorme, I; Fowler, JF; Gagné-Henley, A; Gooderham, M; Haydey, R; Jenkin, P; Landells, I; Lynde, CW; Pariser, DM; Poulin, Y; Rosoph, LA | 1 |
| Bottiglieri, P; Caso, F; Caso, P; Chimenti, MS; Costa, L; Del Puente, A; Peluso, R; Perricone, C; Scarpa, R | 1 |
| Reinke, T | 1 |
| Ballegaard, C; Christensen, R; de Wit, M; Dreyer, L; Gottlieb, A; Jørgensen, TS; Kristensen, LE; Mease, PJ; Skougaard, M; Strand, V; Tarp, S | 1 |
| Chen, R; Duffin, KC; Gottlieb, AB; Levi, E; Merola, JF | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
| Bewley, A; Chen, R; Cirulli, J; Gooderham, M; Green, L; Marcsisin, J; Petric, R; Piguet, V; Reich, K; Soung, J | 1 |
| Armstrong, A; Levi, E | 1 |
| Abignano, G; Fadl, N; Freeston, J; Marzo-Ortega, H; McGonagle, D; Merashli, M; Wenham, C | 1 |
| Holko, P; Kawalec, P; Moćko, P; Pilc, A | 1 |
| Armstrong, AW; Enos, CW; Gottlieb, A; Langley, RG; Lebwohl, M; Merola, JF; Ryan, C; Siegel, MP; Van Voorhees, AS; Weinberg, JM; Whitlock, SM; Wu, JJ | 1 |
| Aelion, JA; Delev, N; Gómez-Reino, JJ; Nash, P; Nguyen, D; Ohson, K; Teng, L; Walsh, J | 1 |
| Di Cesare, A; Lazzeri, L; Pescitelli, L; Prignano, F; Ricceri, F | 1 |
| Harr, T; Lerch, M; Mainetti, C; Terziroli Beretta-Piccoli, B | 1 |
| Queirós, N; Torres, T | 1 |
| Kokkalis, G; Papadavid, E; Rigopoulos, D; Rompoti, N; Theodoropoulos, K | 1 |
| Beltzung, F; D'incan, M; Franck, F; Pellonnet, L; Rouanet, J | 1 |
| Lacour, JP | 1 |
| Fautrel, B; Gossec, L; Mitrovic, S; Reygaerts, T | 1 |
| Guilabert, A; Muñoz-Santos, C; Sola-Ortigosa, J | 1 |
| Bagel, J; Chen, R; Duffin, KC; Goncalves, J; Jackson, JM; Lebwohl, M; Levi, E; Stein Gold, L | 1 |
| Blednov, YA; Da Costa, AJ; Harris, RA; Messing, RO | 1 |
| Blednov, YA; Da Costa, AJ; Harris, RA; Messing, RO; Ponomareva, O; Tarbox, T | 1 |
| Honma, M; Iinuma, S; Ishida-Yamamoto, A; Iwasaki, T; Shibuya, T | 1 |
| Amin, M; Lee, EB; Wu, JJ | 2 |
| Hashimoto, T; Ishii, N; Kamiya, K; Komine, M; Maekawa, T; Murata, S; Ohtsuki, M; Waki, Y | 1 |
| Beck, KM; Bhutani, T; Sekhon, S; Yang, EJ | 1 |
| Amin, M; Egeberg, A; Lee, EB; Wu, JJ | 1 |
| Alessandri, C; Ceccarelli, F; Conti, F; Lucchetti, R; Miranda, F; Perricone, C; Scrivo, R; Spinelli, FR; Truglia, S; Valesini, G | 1 |
| Gómez-Díez, S; Lozano, A; Munguía-Calzada, P; Santos-Juanes, J; Velasco, L | 1 |
| Eto, A; Furue, M; Nakao, M | 1 |
| Gonzalez, V; Molina, I; Monteagudo, C; Montesinos, E; Ramon, MD; Vazquez, B | 1 |
| Baty, D; Berard, F; Bessis, D; Bourrat, E; Castela, E; Chiaverini, C; Kanitakis, J; Lacour, JP; Mazereeuw, J; Morice-Picard, F; Nicolas, JF; Passeron, T; Rozières, A; Tulic, MK; Vabres, P | 1 |
| Correa da Rosa, J; Garcet, S; Krueger, JG; Nograles, K; Schafer, PH | 1 |
| Cho, M; Honda, T; Kabashima, K; Kataoka, T; Otsuka, A; Ueshima, C | 1 |
| Ferrer, DS; Giácaman von der Weth, MM; Guillén, BF; Ninet, VZ; Sánchez-Carazo, JL; Tapial, JM | 1 |
| Bielory, L; Norris, MR | 1 |
| Atzeni, F; Caporali, R; Conti, F; D'Angelo, S; Favalli, EG; Iannone, F; Selmi, C | 1 |
| Al-Anazi, WA; Al-Asmari, AF; Al-Harbi, MM; Al-Harbi, NO; Almutairi, MM; Alotaibi, MR; Alsaad, AM; Alshammari, M; Ansari, MA; Ansari, MN; Bahashwan, S; Imam, F; Khan, MR | 1 |
| Augustin, M; French, LE; Krueger, JG; Pincelli, C; Schafer, PH | 1 |
| Gutiérrez-Ureña, SR; Hernández-Cruz, LI; Jara, LJ; Miranda-Hernández, D; Romo-Rodríguez, R; Saavedra, MA | 1 |
| Hioki, T; Kamiya, K; Kishimoto, M; Komine, M; Ohtsuki, M; Sugai, J | 1 |
| Armstrong, AW; Singh, S | 1 |
| Elman, SA; Merola, JF; Weinblatt, M | 1 |
| Abayaweera, G; Abou-Taleb, HA; AbouElhassan, KM; AbouTaleb, HA; Adair, LS; Adams, E; Addison, O; Addy, I; Akhtar, N; Alten, B; Anesini, J; Añez, R; Angaridis, PA; Aouba, A; Arakawa, K; Aumeeruddy-Elalfi, Z; Bao, LP; Basu, E; Bayraktar, E; Bekkelund, CS; Bell, J; Beraldo, H; Bermúdez, V; Betenbaugh, MJ; Bhattacharya, R; Bienvenu, B; Bolzoni, M; Bootz, F; Borja, JB; Bove, DG; Bowden, ME; Bradsher, C; Brockstedt, D; Brothers, RM; Buschauer, A; Calandriello, L; Caporossi, A; Carba, DB; Carratalà, J; Castella, B; Caviezel, D; Ceccato, R; Charalambidis, G; Charisiadis, A; Chattopadhyay, P; Chen, Q; Chen, W; Chen, Y; Chen, YT; Chen, ZJ; Chen, ZY; Cheng, MA; Cheng, ZB; Cherevko, S; Cheung, IY; Cheung, NV; Chiappini, A; Chiu, YL; Choi, IG; Chough, S; Chung, CY; Cobb, A; Colotto, A; Continentino, MA; Cook, AJMC; Costa, F; Coutsolelos, AG; Cuperus, N; Curtis, BM; Davenport, AJ; de Boysson, H; Dela, F; Deng, XP; Deshayes, S; Dhara, K; Dietrich, D; Dietrich, J; Dilhari, A; Ding, R; Ding, Y; Dirè, S; Dohlmann, TL; Dotsenko, A; Doubrovina, E; Du, K; Du, ZJ; Duvic, M; Eastman, A; Eliakim-Raz, N; Elz, S; Emile, JF; Emmerling, C; Engelhard, MH; Eriksson, JG; Etzold, BJM; Faini, AC; Falsini, B; Farmer, E; Fei, JJ; Ferreira, IP; Föttinger, K; Franconieri, F; Fryda, NJ; Fuentes, I; Galateau-Sallé, F; Ganguly, M; Gani, BA; Gao, X; Gao, XF; Gao, XJ; García-Mendiola, T; Garg, A; Gascon, J; Gayani, B; Gevensleben, H; Gilbert, M; Giudiceandrea, A; Giuliani, N; Gocmen, AY; Goldman, DA; Goltz, D; Gombert, AK; Gomila, A; Goodwin, P; Górnicki, K; Gostin, PF; Graterol, M; Gremillet, C; Grier, S; Grün, AL; Gusakov, A; Halldórsdóttir, HR; Han, L; Han, Z; Hävecker, M; Helge, JW; Heo, K; Hernández, JD; Hindsø, M; Holmen Olofsson, G; Hong, CE; Hong, J; Horenstein, AL; Hosenally, M; Hruz, P; Hsu, HL; Hsu, KC; Hu, SF; Hu, Y; Huang, K; Huang, S; Huang, WH; Humaira, A; Hung, CF; Hung, WS; Huo, XK; Huvinen, E; Idorn, M; Ignatyev, K; Im, WT; Ismaël, IS; Jakobsson, JG; Janaszek-Mańkowska, M; Jeong, GT; Ji, L; Ji, X; Jiang, Y; Jo, IH; Jo, SH; Johnson, AC; Johnson, LE; Kadirvelu, K; Kahnt, A; Kaleta, A; Kamiya, T; Kang, DH; Kang, XH; Kashiwagi, T; Katayama, E; Kawachi, N; Keller, M; Kellermann, L; Khan, T; Khan, ZA; Kharshoum, RM; Khim, JS; Kikuchi, M; Kim, BS; Kim, DS; Kim, DW; Kim, JH; Kim, JJ; Kim, JU; Kim, SK; Kim, WS; Kimura, J; Kiss, C; Knop-Gericke, A; Kobayashi, S; Koivusalo, SB; Kolar, E; Kottegoda, N; Kramer, K; Kristiansen, G; Kruger, AA; Kumar, S; Kumar, V; Kumarage, S; Kursungoz, C; Kushner, BH; Kuwahara, F; Kuzawa, C; Kwon, BO; Landsberg, J; Larsen, S; Lauer, P; Le Luduec, JB; Lee, DW; Lee, H; Lee, HY; Lee, JW; Lee, MJ; Lee, SW; Lefrançois, P; Leibovici, L; Leong, KK; Leong, M; Li, B; Li, D; Li, G; Li, J; Li, YZ; Liang, JH; Liang, X; Liens, A; Ligorio, G; Lin, JD; Lindholm, MG; Liou, MJ; List-Kratochvil, EJW; Litvinov, IV; Liu, F; Liu, S; Liu, Y; Liu, Z; Lohar, S; Lopes, MTP; Lorenzo, E; Lu, X; Lukashuk, L; Lukens, WL; Luo, HR; Luo, L; Luttik, MAH; Ma, Y; MacGowan, A; Mahomoodally, MF; Maissen, S; Malavasi, F; Malhotra, M; Mallik, S; Manna, D; Mans, R; Marangoni, D; Marimpietri, D; Marques, F; Marques, WL; Marsaa, K; Martin Silva, N; Martinez, A; Martínez, MS; Massaia, M; Mayrhofer, KJJ; McDade, T; McNeel, DG; Met, Ö; Micalizio, GC; Modak, S; Morandi, F; Moreau, L; Morla, S; Morrell, AP; Morris, S; Mubarak, Z; Muchlisin, ZA; Munoz, M; Nagao, Y; Nakama, T; Nakamura, H; Nakano, T; Nardi, MV; Nasirian, A; Nelson, MD; Netchiporouk, E; Ni, X; Niess, JH; Nijenhuis, JM; Nikolaou, V; O'Connor, BJ; O'Reilly, RJ; Odobel, F; Ohata, C; Ohyama, B; Olivar, LC; Ordoñez, MG; Ostrovnaya, I; Palmar, J; Panda, S; Pandiyarajan, S; Park, B; Park, H; Park, JH; Park, S; Pasquali, L; Patik, JC; Pearce, CI; Peele, ME; Peng, S; Perera, IC; Petty, JT; Pidko, EA; Pinheiro, CB; Pistoia, V; Pita, M; Planchat, A; Plass, F; Pockes, S; Pradhan, N; Premasudha, P; Pronk, JT; Provost, N; Pujol, M; Qi, P; Qiu, J; Qiu, Z; Quan, J; Quaranta, A; Ra, CH; Rameshan, R; Ranglack, DH; Rausch-Fan, X; Rieger, E; Rivas, JR; Roberts, SS; Rocha, WR; Rodrigues, GLS; Rojas, J; Roy, P; Rozhkova, A; Rufo, S; Rupprechter, G; Saeui, CT; Saha, A; Sakai, M; Salazar, J; Salem, HF; Salgarello, T; Samarakoon, SR; Sandau, C; Sandbeck, DJS; Santos, AF; Santos, VG; Sara, Y; Saslow, SA; Sasseville, D; Sato, S; Sauer, JD; Schlögl, R; Schweiger, MJ; Shashkov, I; Shaw, E; Shen, WQ; Shim, J; Shu, J; Singh, C; Sinha Babu, SP; Sinitsyn, A; Sinitsyna, O; Skadborg, SK; Song, Q; Song, W; Stach-Lempinen, B; Stoddart, M; Stoica, M; Street, SR; Sukwong, P; Sun, CP; Sun, J; Sunwoo, IY; Suresh, S; Szécsényi, Á; Takahashi, T; Takeda, S; Tang, D; Tas, ST; Tebé, C; Teixeira, LR; Teixidor, F; Terrier, B; Teschner, D; Tetzlaff, MT; Theisen, E; Thor Straten, P; Tiitinen, A; Timpel, M; Toccoli, T; Torikai, K; Torres, W; Toscani, D; Trad, S; Tsai, HJ; Tseng, CP; Tucker, WJ; Um, W; Vallejo-Torres, L; van den Broek, M; Van den Heuvel, L; van der Woude, LN; van Maris, AJA; Van Schepdael, A; Vank, C; Verucchi, R; Vigo, JM; Viñas, C; Vogt, TJ; Vuong, C; Wai, H; Wang, B; Wang, D; Wang, H; Wang, JJ; Wang, K; Wang, L; Wang, Q; Wang, YR; Watanabe, S; Watters, AK; Weerasekera, MM; Wei, L; Wheeler, DA; Wiegand, I; Wifling, D; Wijesinghe, GK; Winiczenko, R; Wolker, T; Wu, J; Wu, TC; Wu, YY; Xie, P; Xie, YP; Xu, A; Xu, E; Xu, L; Xu, Z; Yamaguchi, M; Yang, A; Yang, G; Yang, J; Yang, TM; Yang, W; Yang, Y; Yarema, KJ; Yesiltepe, M; Yi, KJ; Yigit, N; Yim, UH; Yin, B; Yu, S; Zengin, G; Zhang, B; Zhang, C; Zhang, GR; Zhang, H; Zhang, J; Zhang, L; Zhang, TY; Zhang, X; Zhang, Y; Zhang, YX; Zhao, H; Zhao, JC; Zhao, Z; Zheng, R; Zhou, W; Zorn Morales, N | 1 |
| Campanati, A; Diotallevi, F; Molinelli, E; Offidani, A; Radi, G | 1 |
| Choy, EH; Gandhi, K; Jugl, SM; Kanters, S; McInnes, IB; Nash, P; Pricop, L; Ritchlin, C; Thom, H | 1 |
| Abignano, G; Del Galdo, F; Laws, P; Marzo-Ortega, H; McGonagle, D | 1 |
| Alegre-de Miquel, V; Magdaleno-Tapial, J; Sánchez-Carazo, JL; Valenzuela-Oñate, C | 1 |
| Chiaverini, C; Kieffer, J; Lacour, JP; Le Duff, F; Montaudié, H; Passeron, T | 1 |
| Firinu, D | 1 |
| Bissonnette, R; Boguniewicz, M; Guttman-Yassky, E; Hanifin, JM; Kilty, I; Purohit, V; Tallman, AM; Wollenberg, A; Zielinski, MA | 1 |
| Knuckles, MLF; Levi, E; Soung, J | 1 |
| Bardazzi, F; Ferrara, F; Patrizi, A; Sacchelli, L | 1 |
| Aras, GA; Bagel, J; Chung, JB; Kircik, LH; Kricorian, G; Samad, AS; Stolshek, BS | 1 |
| Bonafede, MM; Brouillette, MA; Feldman, SR; Mehta, RK; Pelletier, CL; Smith, D; Wilson, KL | 2 |
| Baum, D; Guttman-Yassky, E; Hashim, P; Karalekas, R; Kimmel, G; Lebwohl, MG; Mansouri, Y; Mikhaylov, D; Nia, J; Pavel, A; Singer, G; Taliercio, M; Vekaria, AS; Yao, C | 1 |
| Davelaar, N; Mus, AMC; Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV | 1 |
| Bewley, AP; Calzavara-Pinton, PG; Hansen, JB; Nyeland, ME; Shear, NH; Signorovitch, J | 1 |
| Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV | 1 |
| Chen, C; Gettas, T; Messiah, R; Metyas, S; Quismorio, A; Tomassian, C | 1 |
| Al-Harbi, MM; Al-Harbi, NO; Alanazi, AZ; Alhazzani, K; Aljerian, K; Alsanea, S; Belali, OM; Imam, F; Qamar, W | 1 |
| Chen, M; Estrada, YD; Guttman-Yassky, E; Imafuku, S; Malik, K; Nograles, K; Pavel, AB; Peng, X; Poulin, Y; Shah, N; Simpson, EL; Suarez-Farinas, M; Ungar, B; Wen, HC; Xu, H; Zhou, L | 1 |
| Hashimoto, H; Hoashi, T; Ichiyama, S; Kanda, N; Matsushita, M; Nozawa, K; Saeki, H; Ueno, T | 1 |
| Heffron, CCBB; McCarthy, S; Murphy, M | 1 |
| Ferguson, C; Saini, A; Salkey, K | 1 |
| Andrés Lencina, JJ; Aragón Miguel, R; Calleja Algarra, A; Ortiz Romero, PL; Prieto Barrios, M; Rivera Díaz, R; Velasco Tamariz, V; Vico Alonso, C | 1 |
| Ansai, SI; Hoashi, T; Ichiyama, S; Kanda, N; Komatsu, T; Nagai, K; Saeki, H; Yamada, Y | 1 |
| Bonifati, C; De Felice, C; Graceffa, D; Lora, V; Morrone, A | 1 |
| Pelletier, C; Tian, M; Ung, B; Wu, JJ | 1 |
| Kondoh, A; Mabuchi, T; Shimizu, T; Tokuyama, M; Yamada, T | 1 |
| Hernández-Bel, P; Magdaleno-Tapial, J; Ortiz-Salvador, JM; Subiabre-Ferrer, D; Valenzuela-Oñate, C | 1 |
| Dressler, C; Eisert, L; Nast, A; Pham, PA; Werner, RN | 1 |
| Bianchi, L; Campione, E; Esposito, M; Giunta, A; Manfreda, V | 1 |
| Kotecha, A; Krishnamoorthy, G; Pimentel, J | 1 |
| Mellerio, JE | 1 |
| Dressler, C; Eisert, L; Nast, A; Pham, PA | 1 |
| Abignano, G; Fadl, N; Freeston, J; Marzo-Ortega, H; McGonagle, D; Merashli, M; Vandevelde, C | 1 |
| Peitsch, WK | 1 |
| Annunziata, MC; Fabbrocini, G; Fattore, D; Marasca, C; Panariello, L | 1 |
| Aggarwal, R; Charlton, D; English, JC; Moghadam-Kia, S; Oddis, CV; Smith, K | 1 |
| Azevedo, FA; Don, FA; Fabbrocini, G; Kerdel Don, C; Kerdel, FA; Kerdel, FR | 1 |
| Alalaiwe, A; Anwer, MK; Ezzeldin, E; Fatima, F; Iqbal, M; Mohammad, M | 1 |
| Atzeni, F; Bragazzi, NL; Damiani, G; Franchi, C; Grossi, E; Petrou, S; Pigatto, PD; Radovanovic, D; Rizzi, M; Santus, P; Sarzi-Puttini, P | 1 |
| Fan, C; Feng, C; Gao, Y; He, P; Li, H; Lu, H; Qi, Q; Tang, W; Wu, Y; Yang, X; Zhu, F; Zuo, J | 1 |
| Castellví, I; Corominas, H; Magallares, B; Millan, M; Moya, P; Wilson, N | 1 |
| Cuenca-Barrales, C; Navarro-Triviño, FJ; Ruiz-Villaverde, R; Vega-Castillo, JJ | 1 |
| Atanaskova Mesinkovska, N; Juhász, MLW | 1 |
| Beigel, F; Beissert, S; Gerdes, S; Homey, B; Körber, A; Mössner, R; Pinter, A; Radtke, MA; Staubach-Renz, P | 1 |
| Bo, C; Cao, Y; Chen, L; Jiao, Y; Kong, X; Li, L; Li, S; Liu, P; Liu, Z; Lu, X; Ning, S; Wang, J; Wang, L; Zhang, H | 1 |
| Nakajima, H; Nakajima, K; Okazaki, S; Osawa, R; Sano, S | 1 |
| Batool, S; Imran, S; Majid, I | 1 |
| Aljaser, M; Amar, L; Kircik, LH | 1 |
| Casseres, RG; Dumont, N; Gottlieb, AB; Her, MJ; Kahn, JS; Rosmarin, D | 1 |
| Billionnet, C; Maura, G; Mezzarobba, M; Sbidian, E; Weill, A | 1 |
| Bianchi, L; Campione, E; Cesaroni, GM; Diluvio, L; Lanna, C; Lozzi, F; Mazzilli, S; Palumbo, V | 1 |
| Cline, A; Feldman, SR; Kepley, AL; Kolli, SS | 1 |
| Bardazzi, F; Loi, C; Patrizi, A; Sacchelli, L | 1 |
| Delev, N; Edwards, CJ; Gladman, DD; Guerette, B; Kavanaugh, A; Mease, PJ; Paris, M; Schett, G; Teng, L | 1 |
| Bansal, A; Baradaran, S; Devine, B; Higa, S; Patel, V; Wang, D | 1 |
| Kircik, LH; Pariser, DM; Stein Gold, LF | 1 |
| Eto, A; Furue, M; Kurihara, Y; Nakano, K | 1 |
| Kamiya, K; Kishimoto, M; Komine, M; Ohtsuki, M; Sugai, J | 1 |
| Bogdanos, DP; Brotis, AG; Katsiari, CG; Liaskos, C; Mavropoulos, A; Roussaki-Schulze, A; Sakkas, LI; Simopoulou, T; Zafiriou, E | 1 |
| Dogra, S; Kaushik, A; Narang, T | 1 |
| Lee, E; Reddy, SP; Wu, JJ | 1 |
| Gilhar, A; Keren, A; Laufer Britva, R; Paus, R | 1 |
| Boffini, N; Campochiaro, C; Cariddi, A; Cavalli, G; Dagna, L; De Luca, G; Tomelleri, A; Vanni, D | 1 |
| Bastien, M; Beauchet, A; Becherel, PA; Begon, E; Bilan, P; Boulard, C; Boyé, T; Fougerousse, AC; Gabison, G; Girard, C; Halioua, B; Kemula, M; Kupfer-Bessaguet, I; Le Guyadec, T; Lons-Danic, D; Lorier, E; Maccari, F; Mahé, E; Maillard, H; Mery-Bossard, L; Monfort, JB; Pallure, V; Parier, J; Perrot, JL; Perrussel, M; Pfister, P; Poiraud, C; Quiles-Tsimaratos, N; Steff, M; Sultan, N; Thomas-Beaulieu, D; Vermersch-Langlin, A; Wagner, L; Zeitoun, M | 1 |
| Alessandri, C; Ceccarelli, F; Cipriano, E; Conti, F; Di Franco, M; Lucchetti, R; Miranda, F; Perricone, C; Riccieri, V; Scrivo, R; Spinelli, FR; Truglia, S; Valesini, G | 1 |
| Andrés-Lencina, JJ; Aragón-Miguel, R; Calleja-Algarra, A; Pinilla-Martin, B; Rivera-Díaz, R; Sánchez-Velázquez, A; Vico-Alonso, C | 1 |
| Kamata, M; Nagata, M; Ohtsuki, M; Sato, S; Tada, Y | 1 |
| Hisaw, LD; Kim, MM; Maloney, NJ; Nguyen, KA; Worswick, S | 1 |
| Cantarini, L; Di Scala, G; Emmi, G; Fabiani, C; Iannone, F; Lascaro, N; Leccese, P; Lopalco, G; Rigante, D; Venerito, V | 1 |
| Barcellona, C; Becker, EM; de Lucas, R; Fiorillo, L; Hong, Y; Maes, P; Paller, AS; Paris, M; Zhang, W; Zhang, Z | 1 |
| Chourdakis, V; Georgiou, S; Grafanaki, K; Kyriakou, G; Plachouri, KM | 1 |
| Damiani, G | 1 |
| Bagel, J; Gottlieb, AB; Merola, JF; Natsis, NE; Orbai, AM; Weinberg, JM; Wu, JJ | 1 |
| Babor, M; Jirát, J; Ondo, D; Ridvan, L; Šoóš, M | 1 |
| Chhabra, G; Verma, P | 1 |
| Bianchi, L; Campione, E; Lanna, C; Mazzilli, S; Zangrilli, A | 1 |
| Bryld, LE; Dam, TN; Egeberg, A; Gniadecki, R; Iversen, L; Loft, ND; Rasmussen, MK; Skov, L | 1 |
| Saruwatari, H | 1 |
| Adams, M; Horan, G; Marconi, A; Pincelli, C; Schafer, PH; Truzzi, F | 1 |
| Bartos, G; Dozier, L; Kerdel, F | 1 |
| Yazici, Y | 1 |
| Walker, SL | 1 |
| Hirabayashi, M; Kuwano, Y; Nakashima, C; Nomura, M; Sakakibara, M; Sei, Y; Shimoyama, H | 1 |
| de la Cueva Dobao, P; Eguren Michelena, C; Galán Sánchez, JL | 1 |
| Gandjour, A; Ostwald, DA | 1 |
| Chen, M; Cheng, S; Hatemi, G; Ishigatsubo, Y; Kim, D; Mahr, A; McCue, S; Melikoğlu, M; Paris, M; Song, YW; Takeno, M; Yazici, Y | 1 |
| Boyman, O; Feusi, A; Kolios, AGA; Kündig, T; Nilsson, J; Yawalkar, N | 1 |
| Takeno, M | 1 |
| Feldman, SR; Lopez-Gonzalez, L; Marchlewicz, EH; Martinez, DJ; Mendelsohn, AM; Shrady, G; Zhang, J; Zhao, Y | 2 |
| Alikhan, A; Cirulli, J; Lockshin, B; Schafer, P; Shi, R; Strober, B | 1 |
| Barbieri, M; Capri, S; Loconsole, F; Migliore, A | 2 |
| Ara, M; Belinchón, I; Bustinduy, M; Carrascosa, JM; Herranz, P; Rivera, R | 1 |
| Sugai, S; Taguchi, R; Takamura, S; Teraki, Y | 1 |
| Pérez Ferriols, A | 1 |
| Akiyama, M; Ando, Y; Ohshima, Y; Takama, H; Watanabe, D; Yanagishita, T | 2 |
| Behrens, F; Brunori, M; Coates, LC; Gladman, DD; Guerette, B; Kavanaugh, A; McInnes, I; Mease, PJ; Ogdie, A; Queiro, R; Smolen, JS; Teng, L | 1 |
| Chitkara, D; Danese, S; Fogel, R; Kopoń, A; Neurath, MF; Panaccione, R; Siegel, CA; Simmons, TC; Usiskin, K; Zakko, SF; Zhan, X | 1 |
| Bardazzi, F; Di Altobrando, A; Patrizi, A; Sacchelli, L | 1 |
| Ai, J; Eisinger, D; LaBrie, ST; Medvedeva, IV; Schafer, P; Stokes, ME; Trotter, MWB; Yang, R | 1 |
| Carrascosa de Lome, R; Conde Montero, E; de la Cueva Dobao, P | 1 |
| Hagberg, KW; Jick, S; Persson, R; Vasilakis-Scaramozza, C | 1 |
| De Simone, C; Garcovich, S; Giovanardi, G; Malvaso, D; Peris, K | 1 |
| Fontas, E; Khemis, A; Lacour, JP; Montaudié, H; Moulin, S; Passeron, T | 1 |
| Kikuchi, N; Yamamoto, T | 1 |
| Deshpande, A; Kulkarni, P | 1 |
| Cauthen, A; Lebwohl, M; Lynde, C; Paris, M; Sofen, H; Stein Gold, L; Strober, B; Tyring, S; Van Voorhees, AS; Wang, Y; Zhang, Z | 1 |
| Alegre-de Miquel, V; Alonso-Carpio, M; García-Legaz, M; Magdaleno-Tapial, J; Valenzuela-Oñate, C; Zaragoza-Ninet, MG; Zaragoza-Ninet, V | 1 |
| Caso, F; Chimenti, MS; Costa, L; Del Puente, A; Giacomelli, R; Girolimetto, N; Navarini, L; Ruscitti, P; Scarpa, R | 1 |
| Friedman, AJ; Prussick, RB; Wei, C | 1 |
| Nittala, R; Singh, A | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rahimi, RS; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Tapper, EB; Wong, EB; Wu, JJ | 1 |
| Dapavo, P; Deboli, T; Fraccalvieri, M; Mangia, A; Marchetti Cautela, J; Quaglino, P; Ribero, S; Siliquini, N | 1 |
| Curtis, JR; Khilfeh, I; Pelletier, C; Tian, M; Ung, B; Wu, JJ | 1 |
| Shavit, E; Shear, NH | 1 |
| Kainu, K; Simonsen, S; Skov, L; Todberg, T; Zachariae, C | 1 |
| Marafini, I; Monteleone, G; Salvatori, S; Troncone, E | 1 |
| Iranzo, P; Mascaró, JM; Riquelme-Mc Loughlin, C | 1 |
| Hagberg, KW; Jick, S; Persson, R; Qian, Y; Vasilakis-Scaramozza, C | 2 |
| Bianchi, L; Campione, E; Cesaroni, GM; Chiaramonte, C; Chimenti, MS; Cosio, T; Dattola, A; Galluzzo, M; Gaziano, R; Gisondi, P; Lanna, C; Mazzilli, S; Palumbo, V; Zangrilli, A | 1 |
| Awasthi, R; Dua, K; Khobaragade, S; Madan, JR | 1 |
| Armesto, S; Belinchón, I; Carrascosa, JM; Carretero, G; Del Alcázar, E; Ferran, M; Herranz, P; Herrera-Acosta, E; Hospital, M; Llamas, M; López-Ferrer, A; Martín, I; Mitxelena, MJ; Mollet, J; Montesinos, E; Muñoz, C; Pérez-Barrio, S; Rivera, R; Ruiz-Genao, DP; Ruiz-Villaverde, R; Sahuquillo-Torralba, A; Suárez-Pérez, JA; Valentí, F; Vidal, D; Vilarrasa, E | 1 |
| Bagel, J; Kircik, LH; Kricorian, G; Stolshek, BS; Yang, Y | 1 |
| Camela, E; Cinelli, E; Fabbrocini, G; Megna, M | 1 |
| Augustin, M; Bundy, C; Conrad, C; Cordey, M; Eyerich, K; Greggio, C; Griffiths, CEM; Kleyn, CE; Koscielny, V; Mellars, L; Radtke, MA; Sator, PG; Ståhle, M | 1 |
| Balato, A; Bianchi, L; Campione, E; Cirillo, T; Fabbrocini, G; Malara, G; Trifirò, C | 1 |
| Ceribelli, A; Grigioni, E; Gueli, R; Nigro, O; Pinotti, G; Santis, M; Selmi, C | 1 |
| Balduzzi, V; Bernardini, N; Di Cristofano, C; Di Fraia, M; Mambrin, A; Marchesiello, A; Michelini, S; Petrozza, V; Porta, N; Potenza, C; Proietti, I; Romeo, G; Skroza, N; Tolino, E | 1 |
| Astegiano, M; Cariti, C; Dapavo, P; Ribaldone, DG; Ribero, S; Susca, S; Vernero, M | 1 |
| Bizzoca, R; Cacciapaglia, F; Iannone, F; Lacarpia, N; Lopalco, G; Natuzzi, D; Venerito, V | 1 |
| Atzori, L; Mugheddu, C; Pizzatti, L; Rongioletti, F; Sanna, S | 1 |
| Yazici, H | 1 |
| Ghamrawi, RI; Ghiam, N; Wu, JJ | 1 |
| Botella Estrada, R; de Unamuno Bustos, B; Monte Boquet, E; Rodríguez Serna, M; Sahuquillo-Torralba, A | 1 |
| Armesto, S; González López, MA; González Vela, C | 1 |
| Jiang, YY; Jin, HZ; Shu, D; Wang, WM | 1 |
| Elewski, BE; Ho-Pham, H; Oak, ASW | 1 |
| Anpilogova, EM; Olisova, OY; Svistunova, DA | 1 |
| Cozzio, A; Haller, C; Rubbert-Roth, A; von Kempis, J | 1 |
| Atzori, L; Melis, D; Mugheddu, C; Rongioletti, F; Sanna, S | 1 |
| Chatterjee, D; De, D; Kaushik, A; Kumaran, MS | 1 |
| Kheterpal, MK; Ravichandran, S | 1 |
| Handa, S; Kaushik, A; Narang, T | 1 |
| Akiyama, M; Ando, Y; Ohshima, Y; Shibata, T; Takama, H; Watanabe, D; Yanagishita, T | 1 |
| Carrascosa, JM; Del-Alcazar, E | 1 |
| Bansal, AK; Parmar, PK | 1 |
| Armesto, S; González Vela, C; González-Gay, MA; Naharro Fernández, C; Queiro Silva, R | 1 |
| Bianchi, L; Galluzzo, M; Talamonti, M; Tofani, L | 1 |
| Fernández-Redondo, V; Peña-López, S; Pérez-Feal, P; Pita da Veiga, G; Rodríguez-Granados, MT | 1 |
| Saadoun, D | 1 |
| Dogra, S; Handa, S; Kt, S; Narang, T; Thakur, V | 3 |
| Bastien, M; Beauchet, A; Begon, E; Beneton, N; Boulard, C; Chaby, G; Cinotti, E; Delaunay, J; Fougerousse, AC; Maccari, F; Mahé, E; Mery-Bossard, L; Parier, J; Phan, C; Prignano, F; Reguiai, Z; Romanelli, M; Samimi, M; Thomas-Beaulieu, D | 1 |
| Ezzedine, K; Hamzavi, IH; Qureshi, AA; Vance, TM | 1 |
| Bianchi, L; Campione, E; Cesaroni, GM; Gaziano, R; Lanna, C; Marino, D; Mazzilli, S; Vollono, L | 1 |
| Corallo, C; Cozzani, E; Cutolo, M; Giordano, N; Martinelli, G; Montagna, P; Paolino, S; Parodi, A; Patane, M; Pizzorni, C; Smith, V; Soldano, S; Sulli, A; Tardito, S; Tavilla, P | 1 |
| Blednov, YA; Borghese, CM; Dugan, MP; Harris, RA; Kichili, NR; Messing, RO; Pradhan, S; Thodati, TM | 1 |
| Kalb, RE; Shary, N | 1 |
| Dalamaga, M; Kapniari, E; Papadavid, E | 1 |
| Huang, X; Yuan, Y; Zhang, Y | 1 |
| Alonso-Llamazares, J; Cantrell, W; Kircik, L; Koo, J; Moore, A; Stein Gold, L; Teng, J | 1 |
| Casanova, DM; Di Lernia, V; Ricci, C | 1 |
| Frischhut, N; Ratzinger, G | 1 |
| Alajmi, A; Jfri, A; Nassim, D; Pehr, K | 1 |
| Aarts, P; Prens, EP; van der Zee, HH; van Straalen, KR; Vossen, ARJV | 1 |
| Imafuku, S; Komine, M; Nemoto, O; Ohtsuki, M; Okubo, Y; Petric, R; Schafer, P | 1 |
| Alonso Suárez, J; Beltrán Catalán, E; Blasco Maldonado, C; Daudén Tello, E; García-Merino, A; Herrero Manso, MC; Jiménez Morales, A; Marín-Jiménez, I; Martín-Arranz, MD; Porta Etessam, J; Rodríguez-Sagrado, MA; Rosas Gómez de Salazar, J; Salgado-Boquete, L; Trujillo Martín, E | 1 |
| Czarnowicki, T; Lebwohl, MG; Rosendorff, BP | 1 |
| Gegúndez-Hernández, H; Mateu-Puchades, A; Melgosa-Ramos, FJ; Moneva-Léniz, LM; Prats-Máñez, A; Sánchez-Martínez, EM | 1 |
| Chatterjee, D; Kaushik, A; Raj, D; Vinay, K | 1 |
| Hirahara, L; Kirino, Y; Mizuki, N; Nakajima, H; Soejima, Y; Takase-Minegishi, K; Takeno, M; Takeuchi, M; Yoshimi, R | 1 |
| Kircik, LH; Schlesinger, TE; Tanghetti, E | 1 |
| Eder, L; Sandhu, VK; Yeung, J | 1 |
| Kataoka, S; Nakajima, K; Sano, S; Takaishi, M | 1 |
| Armesto, S; Gómez-Fernández, C; González López, MA; González Vela, C; González-Gay, MA; Illaro, A; López Sundh, AE; Mayorga, J; Naharro Fernández, C; Palmou, N; Sánchez, J | 1 |
| Donaldson, C; Mastin, PJ; Price, AD; Wagler, VD | 1 |
| Aslam, F; Bansal, P; Cusick, A; Goyal, A | 1 |
| Chitkara, D; Danese, S; Usiskin, K | 1 |
| Emeanuru, K; Glynn, M; Guerette, B; Harrold, LR; Liu, M; Mease, PJ; Ogdie, A; Richter, S | 1 |
| Ghoreschi, K; Holstein, J; Meier, K; Solimani, F; Waschke, J | 1 |
| Caffarini, M; Campanati, A; Di Vincenzo, M; Diotallevi, F; Lucarini, G; Offidani, A; Orciani, M; Radi, G | 1 |
| Shah, CA | 1 |
| Annunziata, MC; Apalla, Z; Carrera, C; Fabbrocini, G; Fattore, D; Giacchero, D; Lallas, A; Lallas, K; Lazaridou, E; Nikolaou, V; Ortiz-Brugués, A; Patri, A; Peris, K; Riganti, J; Rigopoulos, D; Romano, MC; Rossi, E; Sibaud, V; Sollena, P; Stratigos, AJ; Voudouri, D | 1 |
| Chen, X; Chen, Y; Li, H; Li, Z; Liang, D; Pan, Y; Su, W; Xie, Y | 1 |
| Foti, C; Frisario, R; Giuffrida, R; Hansel, K; Lospalluti, L; Romita, P; Stingeni, L; Tucci, M | 1 |
| Bagel, J; Hetzel, A; Nelson, E; Riley, C | 1 |
| Buckman, CJ; Cox, K; Dairaghi, DJ; Ho, S; Lim, J; Ma, Y; Patel, DR; Philips, D; Sissons, SE; Urva, S; Zuniga, MS | 1 |
| Georgiou, S; Plachouri, KM | 1 |
| Abittan, BJ; Bares, J; Chima, MA; Chu, J; Del Duca, E; Gagliotti, M; Genece, J; Guttman-Yassky, E; Kim, HJ; Kimmel, G; Lebwohl, MG; Pavel, AB; Singer, GK; Wilding, G | 1 |
| Bi, K; Li, F; Li, Y; Sun, W; Wang, B | 1 |
| Akiyama, M; Ando, Y; Kato, N; Ohashi, W; Ohshima, Y; Takama, H; Watanabe, D; Yanagishita, T | 1 |
| Ekhlassi, E; Lewis, S; Lu, Y; Mhaskar, R; Patel, N; Patel, NS; Sadhwani, D; Seminario-Vidal, L; Zeb, L | 1 |
| Boonen, A; Cheng, S; Landewé, R; McCue, S; Taylor, PC; van der Heijde, D | 1 |
| Barete, S; Bouillet, L; Buffier, S; Cacoub, P; Comarmond, C; Fain, O; Gerfaud-Valentin, M; Gobert, D; Goulenok, T; Jamilloux, Y; Lazaro, E; Le Joncour, A; Misery, L; Saadoun, D; Sacre, K; Sève, P; Vautier, M; Vieira, M | 1 |
| Geat, D; Girolomoni, G; Gisondi, P | 1 |
| Hegde, AR; Jagadish, PC; Jain, S; Kini, SG; Mullick, P; Mutalik, S; Mutalik, SP; Pandey, A | 1 |
| Charlotte, F; Saadoun, D; Vautier, M; Vieira, M | 1 |
| Kurata, M; Ohyama, M | 1 |
| Bagel, J; Lebwohl, M; Papp, K; Paris, M; Sofen, H; Stein Gold, L; Strober, B; Van Voorhees, AS; Wang, Y; Zhang, Z | 1 |
| Bozec, A; Degboé, Y; Goodyear, CS; McInnes, IB; Schett, G; Sokolova, MV; Sood, S; Sunzini, F; Zekovic, A | 1 |
| Conti, F; Laganà, B; Picchianti-Diamanti, A; Rosado, MM; Spinelli, FR | 1 |
| Bakirtzi, K; Ioannides, D; Lallas, A; Papadimitriou, I; Sideris, N; Sotiriou, E; Tsentemeidou, A; Vakirlis, E | 1 |
| Qin, H; Wang, T; Yang, Q; Yin, H; Zhuang, Q | 1 |
| Fan, C; Feng, CL; Li, H; Lu, HM; Lu, QK; Tang, W; Wu, B; Xiang, CG; Yang, XQ | 1 |
| Ariani, A; Becciolini, A; Di Donato, E; Giordano, S; Lucchini, G; Lumetti, F; Mozzani, F; Riva, M; Santilli, D | 1 |
| Morisaka, H; Nakajima, H; Nakajima, K; Nakajima, R; Sano, S | 1 |
| Chen, H; Chen, Y; Li, CH; Quan, G; Wang, Q; Wang, Z; Wu, P; Xie, D; Xu, J; Yang, L; Zhang, J | 1 |
| Choi, Y; Huh, KY; Lee, H; Liu, L; Nissel, J; Palmisano, M; Ramirez-Valle, F; Wang, X | 1 |
| Chat, VS; Kearns, DG; Uppal, S; Wu, JJ | 1 |
| d'Arino, A; Damiani, G; Malagoli, P; Pacifico, A; Pigatto, PDM | 1 |
| Anagnostopoulos, Z; Anastasiadis, G; Antonakopoulos, N; Antoniou, C; Aronis, P; Bassukas, I; Chasapi, V; Drosos, A; Georgiou, S; Ioannides, D; Ioannidou, D; Katsantonis, I; Krasagakis, K; Lazaridou, E; Lefaki, I; Neofotistou, O; Papageorgiou, M; Papakonstantis, M; Patsatsi, A; Protopapa, A; Rigopoulos, D; Roussaki-Schulze, AV; Satra, F | 1 |
| D'Arrigo, G; Malara, G; Politi, C; Testa, A; Trifirò, C; Tripepi, G; Verduci, C | 1 |
| Gerdes, S; Kromer, C; Linker, C; Magnolo, N; Mössner, R; Reich, K; Sabat, R; Wilsmann-Theis, D | 1 |
| Cazzaniga, S; Distel, J; Emelianov, V; Heidemeyer, K; Schlapbach, C; Seyed Jafari, SM; Yawalkar, N | 1 |
| Hathaway, NE; Lyford, WH | 1 |
| Brooksbank, K; Brown, R; Cathcart, S; Ferguson, LD; Gao, X; Harvie, J; McInnes, IB; Paterson, C; Radjenovic, A; Rimmer, D; Sattar, N; Semple, G; Siebert, S; Welsh, P | 1 |
| Aelion, JA; Bird, P; Delev, N; Edwards, CJ; Guerette, B; Kivitz, AJ; Paris, M; Teng, L; Wells, AF | 1 |
| Bornscheuer, UT; Wu, S; Xiang, C | 1 |
| Artamonova, OG; Karamova, AE; Kubanov, AA; Nikonorov, AA; Vasileva, EL; Verbenko, DA | 1 |
| Bianchi, L; Biondi, F; Hansel, K; Marietti, R; Stingeni, L; Tramontana, M | 1 |
| Kaplan, DL; Khilfeh, I; Pelletier, C; Tian, M; Udeze, C; Ung, BL | 1 |
| Rapalli, VK; Roy, A; Sharma, S; Singhvi, G | 1 |
| Hatemi, G; Özdede, A | 1 |
| Fukuda, K; Fukui, S; Kawaai, S; Okada, M; Tamaki, H | 1 |
| Coppi, A; Harper, T; Minocherhomji, S; Paris, M; Wegesser, T | 1 |
| Claudepierre, P; Le Corvoisier, P; Paul, M; Penso, L; Pina Vegas, L; Sbidian, E | 1 |
| Alessandri, C; Ceccarelli, F; Cipriano, E; Conti, F; Lucchetti, R; Perricone, C; Spinelli, FR | 1 |
| Bagel, J; Griffiths, CEM; Guerette, B; Lebwohl, M; Menter, A; Mrowietz, U; Nunez Gomez, N; Reich, K; Shi, R; Strober, B | 1 |
| Bergqvist, C; Dray-Spira, R; Herlemont, P; Meyer, A; Penso, L; Sbidian, E; Weill, A; Zureik, M | 1 |
| Aarts, P; Ardon, CB; Dudink, K; Prens, EP; van der Zee, HH; van Straalen, KR; Vossen, ARJV | 1 |
| Gjersvik, P; Helgesen, ALO; Pripp, AH; Qvigstad, E; Skullerud, KH | 1 |
| Li, A; Wu, Y; Yan, Y; Zhang, Q; Zhang, X | 1 |
| Fujimoto, M; Fujisawa, Y; Furuta, J; Inoue, S; Ishitsuka, Y; Koguchi-Yoshioka, H; Matsumura, Y; Matsuzaka, T; Nakamura, Y; Okiyama, N; Shimano, H; Watanabe, R | 1 |
| Albrecht, L; Bhatia, N; Callis Duffin, K; Chen, M; Gooderham, M; Green, L; Papp, K; Paris, M; Pariser, D; Sofen, H; Stein Gold, L; Wang, Y | 1 |
| Ashraf, R; Dogra, S; Kaushik, A; Narang, T | 1 |
| Chen, X; Jia, Y; Sun, J | 1 |
| Bielory, L; Norris, MR; Valentine, L | 1 |
| Guilabert, A; Muñoz-Santos, C; Sola-Ortigosa, J; Vidal, D | 1 |
| Imafuku, S; Kassir, N; Komine, M; Nemoto, O; Ohtsuki, M; Okubo, Y; Petric, R | 1 |
| Ivanic, MG; Liao, W; Thatiparthi, A; Walia, S; Wu, JJ | 1 |
| Duvic, M; Joshi, TP | 1 |
| Bardazzi, F; Carpanese, MA; Conti, A; Corazza, M; Cortelazzi, C; D'Adamio, S; DI Lernia, V; DI Nuzzo, S; Filippi, F; Iezzi, L; Lasagni, C; Odorici, G; Patrizi, A; Peccerillo, F; Tabanelli, M | 1 |
| Egawa, S; Ito, M; Kamata, M; Mizukawa, I; Shimizu, T; Tada, Y; Takeshima, R; Uchida, H; Watanabe, A | 1 |
| Bakirtzi, K; Ioannides, D; Kougkas, N; Lallas, A; Lazaridou, E; Papadimitriou, I; Sotiriou, E; Vakirlis, E | 1 |
| Furukawa, F; Kataoka, K; Makino, T; Matsui, Y; Mizawa, M; Nakano, H; Sawamura, D; Shimizu, T; Takemoto, K; Yoto, A | 1 |
| Ichimura, Y; Inoue, S; Konishi, R; Nomura, T; Okiyama, N; Tanaka, R | 1 |
| Ahmed, SMA; Brazzelli, V; Isoletta, E; Klersy, C; Lilleri, D; Musella, V; Tomasini, CF; Vassallo, C; Volontè, M; Zelini, P | 1 |
| Liang, J; Sun, X; Zhang, F; Zhuang, R; Zou, B | 1 |
| Devani, AR; Georgakopoulos, JR; Gooderham, MJ; Jain, V; Lansang, P; Lytvyn, Y; Mufti, A; Prajapati, VH; Vender, R; Yeung, J | 1 |
| Doll, M; Dorn, B; Grasmik, T; Hrgovic, I; Jakob, T; Meissner, M; Otto, M | 1 |
| Bobyr, I; Campanati, A; Diotallevi, F; Giannoni, M; Martina, E; Offidani, A; Radi, G; Rizzetto, G | 1 |
| Antoñanzas, J; Estenaga, Á; Rodríguez-Garijo, N; Salido-Vallejo, R; Tomás-Velázquez, A | 1 |
| Hirahara, L; Horita, N; Iizuka, Y; Kirino, Y; Mizuki, N; Nakajima, H; Namkoong, HO; Soejima, Y; Takase-Minegishi, K; Takeno, M; Takeuchi, M; Yoshimi, R | 1 |
| Feldman, SR; Hoit Marchlewicz, E; Lopez-Gonzalez, L; Martinez, DJ; Mendelsohn, AM; Shrady, G; Zhang, J; Zhao, Y | 1 |
| Freitag, L; Hohenforst-Schmidt, W; Huang, H; Kosmidis, C; Kougkas, N; Lallas, A; Petridis, D; Sardeli, C; Zarogoulidis, P | 1 |
| Camela, E; Cinelli, E; Fabbrocini, G; Megna, M; Ocampo-Garza, SS; Ruggiero, A | 1 |
| Crasto, D; Dorgham, N; Skopit, S | 1 |
| Arlégui, H; Bachelez, H; Beneton, N; Bettuzzi, T; Beylot-Barry, M; Chosidow, O; Dupuy, A; Joly, P; Jullien, D; Mahé, E; Paul, C; Richard, MA; Sbidian, E; Tubach, F; Viguier, M | 1 |
| Murakami, M; Sayama, K; Utsunomiya, R; Watanabe, T; Yatsuzuka, K; Yoshida, S | 1 |
| Borroni, RG; Cortese, A; Costanzo, A; Gargiulo, L; Narcisi, A; Pavia, G; Sanna, F; Valenti, M | 1 |
| Contassot, E; Fenini, G; French, LE; Klug, A; Maul, JT; Meier-Schiesser, B; Mellett, M; Ramirez-Fort, MK; Schafer, P; Winkelbeiner, N | 1 |
| Abril-Pérez, C; Botella-Estrada, R; Navarro-Mira, MÁ; Palacios-Diaz, RD | 1 |
| Chen, M; Cheng, S; Dobashi, H; Ishigatsubo, Y; Kishimoto, M; Kono, H; McCue, S; Paris, M; Sugii, S; Takeno, M; Tanaka, Y | 1 |
| Ikumi, K; Kanayama, Y; Morita, A; Nakada, A; Nishihara, H; Sagawa, Y; Torii, K | 1 |
| de la Brassinne, M; Ghislain, PD; Hillary, T; Lam Hoai, XL; Lambert, J; Roquet-Gravy, PP; Segaert, S | 1 |
| de Vlam, K; Di Romana, S; Kaiser, MJ; Lories, R; Remans, P; Toukap, AN; Van den Berghe, M; Van den Bosch, F; Vanhoof, J | 1 |
| Boda, F; Dobó, M; Foroughbakhshfasaei, M; Szabó, ZI; Tóth, G | 1 |
| Augustin, M; Blome, C; Bundy, C; Chachos, E; Griffiths, CEM; Hewitt, RM; Kleyn, CE; Newi, AL; Sommer, R | 1 |
| Sloan, SB | 1 |
| Blass, B; Durig, T; Fassihi, R; Zhang, Q | 1 |
| Bernardini, N; Maddalena, P; Mambrin, A; Marchesiello, A; Marraffa, F; Potenza, C; Proietti, I; Rossi, G; Skroza, N; Tolino, E; Volpe, S | 1 |
| Fakharzadeh, S; Lucas, J; PharmD, SL; PhD, NL; Teeple, A; Villacorta, R | 1 |
| Aichelburg, MC; Anzengruber, F; Graf, V; Hafner, J; Itzlinger-Monshi, B; Perschy, L; Rappersberger, K; Vujic, I | 1 |
| Delaumenie, S; Fourmond, S; Gourin, MP; Gutierrez, B; Ly, KH | 1 |
| Ábalos-Aguilera, MDC; Añón-Oñate, I; Arias de la Rosa, I; Barbarroja, N; Collantes-Estévez, E; Escudero-Contreras, A; Gómez-García, I; Guzmán-Ruiz, R; Ladehesa-Pineda, ML; López-Medina, C; López-Montilla, MD; López-Pedrera, C; Luque-Tévar, M; Malagón, MM; Patiño-Trives, AM; Pérez-Galán, MJ; Pérez-Sánchez, C; Román-Rodríguez, C; Ruiz, D | 1 |
| Annunziata, A; Di Caprio, N; Fabbrocini, G; Megna, M; Potestio, L; Tajani, A | 1 |
| Claudepierre, P; Pina Vegas, L; Sbidian, E | 2 |
| Berlin, JA; Davis, KJ; Desai, RJ; Gagne, JJ; Suruki, RY | 1 |
| Kircik, L; Ozyurekoglu, E | 1 |
| Bergman, M; Gladman, DD; Jardon, S; Kavanaugh, A; Mease, PJ; Ogdie, A; Richter, S; Smolen, JS; Teng, L; Wells, AF | 1 |
| Anagnostopoulos, Z; Anastasiadis, G; Antonakopoulos, N; Aronis, P; Bassukas, I; Chasapi, V; Drosos, A; Ioannides, D; Kalinou, C; Kekki, A; Krasagakis, K; Lazaridou, E; Lefaki, I; Neofotistou, O; Oikonomou, C; Papadavid, E; Papageorgiou, M; Papakonstantis, M; Pokas, E; Protopapa, A; Rigopoulos, D; Rovithi, E; Tampouratzi, E; Zafiriou, E | 1 |
| Alahmadi, RA; Alamri, AM; Aljefri, YE; Alkhamisi, TA; Alkhunani, TA; Alraddadi, AA; Ghaddaf, AA | 1 |
| Bognar, K; Broder, MS; Chang, E; Desai, P; Husni, E; Kaplan, D; Khilfeh, I; Paydar, C; Richter, S; Yan, J | 1 |
| Almodóvar González, R; Díaz González, F; Gratacós, J; Montilla Morales, C; Pascual Alfonso, E; Sanz Sanz, J; Torre Alonso, JC | 1 |
| Nidhal Ghazy, D; Rahmah Abu-Raghif, A | 1 |
| Bordallo-Landa, J; Galache-Osuna, C; Lozano, A; Reyes-García, S; Salgueiro, E; Santos-Juanes, J; Vázquez-López, F | 1 |
| Cowan, TL; Murrell, DF; Wilson, A | 1 |
| Abushal, AS; Aleanizy, FS; Alqahtani, FY; Alsarra, IA; Haq, N; Iqbal, M; Shakeel, F | 1 |
| Calianno, G; Chiricozzi, A; Foti, C; Romita, P | 1 |
| Bansal, AK; Parmar, PK; Rohit, A; Sharma, N; Wasil Kabeer, S | 1 |
| Bonet, M; Torrente-Segarra, V | 1 |
| Dobashi, H; Kadowaki, N; Kameda, T; Kato, M; Mino, R; Miyagi, T; Mizusaki, M; Nakashima, S; Shimada, H; Sugihara, K; Ueeda, K; Ushio, Y; Wakiya, R | 1 |
| Ouyang, F | 1 |
| Expósito Serrano, V; Garbayo Salmons, P; Ribera Pibernat, M; Romaní de Gabriel, J | 1 |
| Arroyo-Andrés, J; Falkenhain-López, D; García-Donoso, C; Montero-Menárguez, J; Postigo-Llorente, C; Sánchez-Velázquez, A | 1 |
| Sui, D; Yu, H | 1 |
| Alberio, L; Aliotta, A; Blum, S; Dumusc, A; Tsilimidos, G | 1 |
| Alinaghi, F; Egeberg, A; Gyldenløve, M; Skov, L; Zachariae, C | 1 |
| Amato, G; Andracco, R; Ariani, A; Arrigoni, E; Becciolini, A; Bravi, E; Bruzzese, V; Caccavale, R; Colina, M; De Lucia, F; Del Medico, P; Di Donato, E; Farina, A; Ferrero, G; Foti, R; Franchina, V; Fusaro, E; Girelli, F; Ianniello, A; Lucchini, G; Lumetti, F; Marchetta, A; Molica Colella, AB; Molica Colella, F; Mozzani, F; Parisi, S; Paroli, M; Platè, I; Salvarani, C; Sandri, G; Santilli, D; Scolieri, P; Visalli, E; Volpe, A | 1 |
| Chen, M; Cheng, S; Hatemi, G; Kim, D; Mahr, A; McCue, S; Melikoğlu, M; Paris, M; Takeno, M; Yazici, Y | 1 |
| Agud-Dios, M; Arroyo-Andrés, J; Postigo-Lorente, C; Rubio-Muñiz, C | 1 |
| Lé, AM; Puig, L; Torres, T | 1 |
| Cheng, Z; Meng, X; Wang, M | 1 |
| Dogra, S; Mehta, H; Sharma, A | 1 |
| Azuma, N; Matsui, K | 1 |
| García-Verdú, E; González-Cañete, M; Lario, AR; Medina-Montalvo, S; Pinto-Pulido, EL; Piteiro-Bermejo, AB; Polo-Rodríguez, I; Trasobares-Marugán, L; Vega-Díez, D | 1 |
| Cordey, M; Jick, S; Paris, M; Persson, R | 1 |
| Amato, G; Baccano, G; Dal Bosco, Y; Foti, R; Visalli, E | 1 |
| Baddoo, M; Bitar, C; Boh, E; Brag, K; Foutouhi, S; Harms, PW; Liu, D; Meyers, J; Ninh, T; Radosta, S; Saba, NS; Stumpf, B | 1 |
| Conti, A; Tiberio, R | 1 |
| Batish, T; Firsick, E; Grigsby, K; Kanadibhotla, S; LeBlanc, K; Ledford, C; Ozburn, A; Reyes, KV; Smith, D; Townsley, K; Tran, A | 1 |
| Di Cesare, A; Fastame, MT; Prignano, F; Rosi, E | 1 |
| Agrogianni, A; Gerochristou, M; Gregoriou, S; Kontochristopoulos, G; Rigopoulos, D; Tsiogka, A | 1 |
| Estevinho, T; Lé, AM; Torres, T | 1 |
| Battocchio, S; Bettolini, L; Calzavara-Pinton, P; Maione, V; Tonon, F; Venturuzzo, A | 1 |
| Gooderham, MJ; Hong, HC; Litvinov, IV | 1 |
| Aziz, HC; Becker, HC; Beneze, A; Bess, J; Crabbe, JC; Eisenstein, TK; Firsick, EJ; Grigsby, KB; Light, JM; Lopez, MF; Mangieri, RA; Mason, BJ; Meissler, JJ; Metten, P; Miller, J; Morrisett, RA; Ozburn, AR; Quello, S; Roberto, M; Roberts, AJ; Shadan, F; Skinner, M; Townsley, KG | 1 |
| Brembach, TC; Gerdes, S; Ghoreschi, K; Kromer, C; Mössner, R; Reich, K; Sabat, R; Wilsmann-Theis, D; Witte, K; Wolk, K | 1 |
| Alsukait, S; Cohen, SR; Cunningham, KN; Dumont, N; Gao, DX; Kachuk, C; Learned, C; Rosmarin, D; Zipeto, A | 1 |
| Mahé, E | 1 |
| Creus-Vila, L; Esquius, M; Fusta-Novell, X | 1 |
| Cabas, N; De Vita, S; Pizzolitto, S; Quartuccio, L; Turina, M | 1 |
| Armstrong, AW; Banerjee, S; Blauvelt, A; Colston, E; Gooderham, M; Imafuku, S; Kundu, S; Linaberry, M; Morita, A; Papp, KA; Schoenfeld, S; Strober, B; Szepietowski, JC; Thaçi, D; Throup, J; Warren, RB | 1 |
| Bagel, J; Banerjee, S; Colston, E; Foley, P; Gordon, KB; Kircik, L; Kundu, S; Linaberry, M; Papp, KA; Paul, C; Rich, P; Sekaran, C; Sofen, H; Strober, B; Thaçi, D; Throup, J | 1 |
| Azib, S; Becquart, C; Cottencin, AC; Darras, S; Dezoteux, F; Duparc, A; Faiz, S; Florin, V; Lehembre, SD; Podevin, P; Staumont-Salle, D | 1 |
| Gebauer, K; Zhang, L | 1 |
| Feng, Y; Huang, C; Xia, J; Yin, X; Yin, Z; Zhang, M | 1 |
117 review(s) available for thalidomide and apremilast
| Article | Year |
|---|---|
CC-1088 Celgene.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Clinical Trials as Topic; Contraindications; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Industry; Humans; Inflammation; Myelodysplastic Syndromes; Phosphodiesterase Inhibitors; Thalidomide; Withholding Treatment | 2005 |
[New therapeutic targets in psoriatic arthritis].
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antirheumatic Agents; Arthritis, Psoriatic; Bone Remodeling; Clinical Trials, Phase III as Topic; Cyclic AMP; Cytokines; Denosumab; Disease Progression; Drug Resistance; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Janus Kinases; Lymphocyte Activation; Lymphocyte Depletion; Molecular Targeted Therapy; Morpholines; Oxazines; Phosphodiesterase 4 Inhibitors; Pyridines; Pyrimidines; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Apremilast as a treatment for psoriasis.
Topics: Animals; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2012 |
Phosphodiesterase 4-targeted treatments for autoimmune diseases.
Topics: Autoimmune Diseases; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Phosphodiesterase 4 Inhibitors; Rolipram; Thalidomide | 2013 |
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Clinical Trials, Phase II as Topic; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide | 2013 |
Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012).
Topics: Administration, Oral; Aminopyridines; Animals; Benzamides; Cyclopropanes; Drug Approval; Drug Delivery Systems; Drug Design; Drug Industry; Humans; Patents as Topic; Phosphodiesterase 4 Inhibitors; Thalidomide | 2013 |
Apremilast for the treatment of psoriatic arthritis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biopharmaceutics; Drug Discovery; Humans; Injections, Intra-Articular; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2014 |
Apremilast: first global approval.
Topics: Adult; Arthritis, Psoriatic; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Approval; Humans; Molecular Structure; Phosphodiesterase 4 Inhibitors; Thalidomide | 2014 |
A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic AMP; Dermatitis, Atopic; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Psoriasis; Thalidomide; Tissue Distribution | 2014 |
Apremilast (otezla) for psoriatic arthritis.
Topics: Animals; Arthritis, Psoriatic; Gastrointestinal Diseases; Humans; Phosphodiesterase 4 Inhibitors; Randomized Controlled Trials as Topic; Thalidomide | 2014 |
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; Inflammation; Inflammatory Bowel Diseases; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sulfones; Thalidomide; Thiazoles | 2014 |
Novel treatments with small molecules in psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Humans; Janus Kinases; Phosphodiesterase Inhibitors; Thalidomide | 2014 |
[Spondyloarthritis including psoriatic arthritis].
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Certolizumab Pegol; Comorbidity; Cooperative Behavior; Diagnosis, Differential; Etanercept; Germany; Gout; Guideline Adherence; HLA-B27 Antigen; Humans; Immunoglobulin Fab Fragments; Immunoglobulin G; Interdisciplinary Communication; Metabolic Syndrome; Polyethylene Glycols; Receptors, Tumor Necrosis Factor; Referral and Consultation; Sacroiliitis; Spondylarthropathies; Spondylitis, Ankylosing; Thalidomide | 2014 |
Therapeutic development in psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Humans; Immunologic Factors; Interleukin-23; Phosphodiesterase Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Treatment Outcome | 2014 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Psoriatic arthritis for the dermatologist.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthralgia; Arthritis, Psoriatic; Dermatology; Drug Resistance; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Methotrexate; Protein Kinase Inhibitors; Thalidomide; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Certolizumab Pegol; Drug Approval; Drug Therapy, Combination; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Polyethylene Glycols; Thalidomide; United States; United States Food and Drug Administration; Ustekinumab | 2015 |
Emerging oral drugs for psoriasis.
Topics: Administration, Oral; Animals; Dermatologic Agents; Drug Approval; Drug Design; Humans; Psoriasis; Severity of Illness Index; Thalidomide; United States; United States Food and Drug Administration | 2015 |
Drug safety evaluation of apremilast for treating psoriatic arthritis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Clinical Trials, Phase III as Topic; Drug Monitoring; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide | 2015 |
New systemic therapies for psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Factors; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide | 2015 |
Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Clinical Trials, Phase III as Topic; Humans; Phosphodiesterase 4 Inhibitors; Thalidomide | 2015 |
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Topics: Administration, Oral; Animals; Arthritis, Psoriatic; Drug Administration Schedule; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Remission Induction; Severity of Illness Index; Thalidomide; Treatment Outcome | 2015 |
Apremilast for the treatment of psoriasis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Clinical Trials as Topic; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2015 |
Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide | 2015 |
▼ Apremilast for psoriasis and psoriatic arthritis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Psoriasis; Thalidomide | 2015 |
Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Autoimmunity; Bone Morphogenetic Proteins; Cytokines; Fibrocartilage; Humans; Interleukin-22; Interleukin-23; Interleukins; Magnetic Resonance Imaging; Methotrexate; Rheumatic Diseases; Rituximab; Spondylarthropathies; Tendinopathy; Thalidomide; Tumor Necrosis Factor-alpha; Versicans | 2016 |
Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Disease Management; Humans; Molecular Targeted Therapy; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Topics: Clinical Trials, Phase II as Topic; Depression; Drug Interactions; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Weight Loss | 2015 |
Apremilast for the treatment of psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Humans; Phosphodiesterase 4 Inhibitors; Thalidomide | 2015 |
Systemic Agents for Severe Atopic Dermatitis in Children.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Child; Cyclosporine; Dermatitis, Atopic; Drug Administration Routes; Humans; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Severity of Illness Index; Thalidomide | 2015 |
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Cyclosporine; Disease Progression; Humans; Immunosuppressive Agents; Insurance, Health, Reimbursement; Keratolytic Agents; Medication Adherence; Methotrexate; Psoriasis; Symptom Flare Up; Thalidomide | 2016 |
An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Psoriatic; Bayes Theorem; Biological Products; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Costs and Cost Analysis; Health Care Costs; Humans; Methotrexate; Models, Economic; Network Meta-Analysis; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2016 |
Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Diarrhea; Headache; Humans; Nausea; Psoriasis; Thalidomide; Treatment Outcome | 2016 |
Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Evidence-Based Medicine; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide; Treatment Outcome; Ustekinumab | 2016 |
Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Humans; Psoriasis; Severity of Illness Index; Technology Assessment, Biomedical; Thalidomide | 2016 |
A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Dose-Response Relationship, Drug; Humans; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Treatment Outcome | 2016 |
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Quality-Adjusted Life Years; Surveys and Questionnaires; Thalidomide; Tumor Necrosis Factor-alpha | 2016 |
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Chronic Disease; Humans; Quality of Life; Severity of Illness Index; Thalidomide | 2016 |
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammation; Inflammation Mediators; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide | 2016 |
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prognosis; Psoriasis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Clinical Trials as Topic; Humans; Psoriasis; Thalidomide | 2016 |
Itch in Psoriasis Management.
Topics: Adaptation, Psychological; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Doxepin; Histamine Antagonists; Humans; Mianserin; Mirtazapine; Paroxetine; Pruritus; Psoriasis; Social Support; Thalidomide; Ultraviolet Therapy | 2016 |
[Not Available].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Clinical Trials as Topic; Dermatologic Agents; Humans; Randomized Controlled Trials as Topic; Thalidomide; Ustekinumab | 2016 |
Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic; Humans; Immunotherapy; Interleukin-12; Interleukin-23; Phosphodiesterase 4 Inhibitors; Thalidomide; Tumor Necrosis Factor-alpha; Ustekinumab | 2017 |
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Disease Management; Glucocorticoids; Humans; Methotrexate; Practice Guidelines as Topic; Societies, Medical; Thalidomide; Tumor Necrosis Factor-alpha; Ustekinumab | 2016 |
New targets in psoriatic arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cyclophosphamide; Etanercept; Humans; Infliximab; Methotrexate; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Ustekinumab | 2016 |
New treatment targets for axial spondyloarthritis.
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-17; Interleukin-23; Molecular Targeted Therapy; Rituximab; Spondylarthropathies; Spondylitis, Ankylosing; Thalidomide; Tumor Necrosis Factor-alpha; Ustekinumab | 2016 |
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Dose-Response Relationship, Drug; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2017 |
Apremilast for the management of moderate to severe plaque psoriasis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide | 2017 |
Apremilast for the treatment of psoriatic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Humans; Thalidomide | 2017 |
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Topics: Aminopyridines; Autoimmune Diseases; Benzamides; Boron Compounds; Cyclopropanes; Eye Diseases; Humans; Immunologic Factors; Intestinal Diseases; Phosphodiesterase 4 Inhibitors; Skin Diseases; Thalidomide | 2017 |
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome; Weight Loss | 2018 |
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Evaluation, Preclinical; Humans; Inflammatory Bowel Diseases; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Thalidomide | 2017 |
Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Bayes Theorem; Humans; Placebos; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome; Ustekinumab | 2018 |
Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis.
Topics: Adalimumab; Administration, Oral; Dermatologic Agents; Humans; Interleukin-17; Janus Kinase Inhibitors; Prevalence; Pruritus; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome; Ultraviolet Therapy | 2018 |
Small molecule therapy for managing moderate to severe psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Humans; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Small Molecule Libraries; Thalidomide; Treatment Outcome | 2017 |
New treatment paradigms in spondyloarthritis.
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Dermatologic Agents; Humans; Spondylarthritis; Spondylarthropathies; Spondylitis, Ankylosing; Thalidomide; Tumor Necrosis Factor-alpha; Ustekinumab | 2018 |
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Drug Substitution; Humans; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha; Ustekinumab | 2017 |
Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Biological Therapy; Epidemiologic Studies; Female; Humans; Middle Aged; Molecular Targeted Therapy; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Thalidomide; Treatment Outcome | 2018 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Comparative Effectiveness Research; Humans; Remission Induction; Thalidomide; Time Factors; Treatment Outcome; Ustekinumab | 2018 |
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Topics: Acitretin; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Certolizumab Pegol; Cyclosporine; Dermatologic Agents; Etanercept; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Psoriasis; Thalidomide; Ustekinumab | 2018 |
Current Perspectives on Erythema Multiforme.
Topics: Acyclovir; Dapsone; Drug-Related Side Effects and Adverse Reactions; Erythema Multiforme; Herpes Simplex; Histiocytes; Humans; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Practice Guidelines as Topic; Simplexvirus; Skin; T-Lymphocytes; Thalidomide | 2018 |
HIV-Associated Psoriasis.
Topics: Adrenal Cortex Hormones; Biological Therapy; Contraindications, Drug; Diagnosis, Differential; Disease Management; HIV Infections; Humans; Immunosuppressive Agents; Phototherapy; Prevalence; Pseudolymphoma; Psoriasis; Scabies; Syphilis; Syphilis, Cutaneous; Thalidomide; Tumor Necrosis Factor-alpha | 2018 |
Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Belgium; Biological Products; Certolizumab Pegol; Comorbidity; Fatigue; Female; France; Humans; Internationality; Male; Pain Measurement; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Switzerland; Thalidomide; Treatment Outcome | 2018 |
Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammation Mediators; Interleukin-17; Interleukin-22; Interleukins; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Treatment Outcome | 2018 |
Targeted drugs in spondyloarthritis during pregnancy and lactation.
Topics: Animals; Breast Feeding; Cytokines; Female; Humans; Janus Kinase Inhibitors; Lactation; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Pregnancy; Spondylarthritis; T-Lymphocytes; Thalidomide | 2018 |
Oral small molecules for psoriasis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Patient Selection; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Thiazoles | 2018 |
Targeted therapies for psoriatic arthritis: an update for the dermatologist.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic; Dermatologic Agents; Dermatology; Humans; Interleukin-17; Interleukin-23; Janus Kinase Inhibitors; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Thalidomide; Tumor Necrosis Factor-alpha | 2018 |
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Comparative Effectiveness Research; Etanercept; Humans; Infliximab; Network Meta-Analysis; Randomized Controlled Trials as Topic; Thalidomide | 2018 |
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
Topics: Acetamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Dermatitis, Atopic; Drug Approval; Humans; Immune System; Inflammation; Phosphodiesterase Inhibitors; Phthalic Acids; Pyridines; Quinazolines; Risk; Skin; Thalidomide | 2019 |
Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Middle Aged; Nail Diseases; Psoriasis; Thalidomide | 2018 |
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Confidence Intervals; Humans; Infliximab; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Time Factors; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2019 |
Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Dermatologic Agents; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Infliximab; Leflunomide; Methotrexate; Randomized Controlled Trials as Topic; Sulfasalazine; Thalidomide; Ustekinumab | 2019 |
Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Bayes Theorem; Humans; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2019 |
The use of phosphodiesterase inhibitors for the treatment of alopecia.
Topics: Alopecia; Caffeine; Cicatrix; Clinical Trials as Topic; Humans; Phosphodiesterase Inhibitors; Sildenafil Citrate; Thalidomide | 2020 |
[Gastrointestinal side effects of apremilast : Characterization and management].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Gastrointestinal Diseases; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2019 |
A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data.
Topics: Administration, Oral; Biological Products; Certolizumab Pegol; Dermatologic Agents; Humans; Injections; Psoriasis; Thalidomide; Ustekinumab | 2019 |
Treating psoriasis: patient assessment, treatment goals, and treatment options.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Biological Products; Body Surface Area; Comorbidity; Dermatologic Agents; Humans; Mass Screening; Patient Care Planning; Patient Reported Outcome Measures; Phototherapy; Practice Guidelines as Topic; Pruritus; Psoriasis; Severity of Illness Index; Thalidomide; Tumor Necrosis Factor-alpha; Ustekinumab | 2019 |
One stone, two birds: Improvement of early-onset vitiligo under apremilast in a patient with plaque psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Early Diagnosis; Humans; Male; Middle Aged; Prognosis; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; Vitiligo | 2019 |
Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast.
Topics: Aged; Arthritis, Psoriatic; Biological Products; Dermatologic Agents; Humans; Medicare; Phototherapy; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; United States | 2020 |
Management of Behçet syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Behcet Syndrome; Humans; Thalidomide; Ustekinumab | 2020 |
Positioning of apremilast in treatment of Behçet's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Humans; Thalidomide | 2020 |
The Use of Apremilast in Psoriasis: A Delphi Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Consensus; Delphi Technique; Foot Dermatoses; Hand Dermatoses; Humans; Patient Satisfaction; Psoriasis; Quality of Life; Scalp Dermatoses; Thalidomide | 2020 |
Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Oral Ulcer; Phosphodiesterase 4 Inhibitors; Thalidomide | 2020 |
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Hidradenitis Suppurativa; Humans; Male; Middle Aged; Thalidomide | 2020 |
Analytical Methods for Determination of Apremilast from Bulk, Dosage Form and Biological Fluids: A Critical Review.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Chemistry Techniques, Analytical; Chromatography; Drug Monitoring; Humans; Spectrum Analysis; Thalidomide | 2021 |
Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Psoriatic; Azetidines; Humans; Janus Kinases; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Thalidomide; Treatment Outcome | 2020 |
An update on the safety of apremilast for the treatment of plaque psoriasis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Medication Adherence; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2020 |
TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Oligonucleotides; Phosphodiesterase 4 Inhibitors; Thalidomide; Thiazoles; Transforming Growth Factor beta | 2020 |
Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature.
Topics: Adult; Arthritis, Psoriatic; Humans; Immune Checkpoint Inhibitors; Male; Nivolumab; Phosphodiesterase 4 Inhibitors; Programmed Cell Death 1 Receptor; Thalidomide; Treatment Outcome | 2020 |
Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Europe; Humans; Psoriasis; Thalidomide; United States | 2022 |
Apremilast for psoriasis treatment.
Topics: Administration, Oral; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide | 2020 |
Optimizing the Treatment of Moderate-to-Severe Psoriasis in Older Adults.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Comorbidity; Drug Interactions; Female; Humans; Middle Aged; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Biological Products; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Humans; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Apremilast in dermatology: A review of literature.
Topics: Arthritis, Psoriatic; Behcet Syndrome; Dermatology; Humans; Thalidomide | 2020 |
Apremilast and its role in psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Humans; Phosphodiesterase 4 Inhibitors; Randomized Controlled Trials as Topic; Thalidomide | 2020 |
On- and Off-Label Uses of Apremilast in Dermatology.
Topics: Humans; Off-Label Use; Phosphodiesterase 4 Inhibitors; Psoriasis; Skin Diseases; Thalidomide | 2020 |
Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
Topics: Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Humans; Phosphodiesterase 4 Inhibitors; Thalidomide | 2021 |
Apremilast Uses and Relevance to the Military.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Military Personnel; Thalidomide | 2021 |
Generalized granuloma annulare successfully treated with apremilast: report of two cases and literature review.
Topics: Adult; Aged; Female; Granuloma Annulare; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Thalidomide; Treatment Outcome | 2021 |
An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Topics: Adult; Behcet Syndrome; Humans; Oral Ulcer; Quality of Life; Thalidomide | 2021 |
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Humans; Nail Diseases; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
Topics: Adalimumab; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Biological Products; CD40 Antigens; Complement Inactivating Agents; Epoxide Hydrolases; Etanercept; Hidradenitis Suppurativa; Humans; Immunologic Factors; Infliximab; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Interleukin-17; Interleukin-23; Janus Kinase Inhibitors; Protein Kinase Inhibitors; Receptors, Interleukin-8A; Receptors, Interleukin-8B; Severity of Illness Index; Surgical Procedures, Operative; Thalidomide; Tumor Necrosis Factor Inhibitors | 2021 |
Comparison of structural components and functional mechanisms within the skin vs. the conjunctival surface.
Topics: Antibodies, Monoclonal, Humanized; Conjunctiva; Dermatitis, Atopic; Eczema; Humans; Psoriasis; Skin; Thalidomide; Treatment Outcome | 2021 |
Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide | 2021 |
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options.
Topics: Anti-Infective Agents; Antimalarials; Biological Therapy; Comorbidity; Dermatologic Agents; Diabetes Complications; Diagnosis, Differential; Glucocorticoids; Granuloma Annulare; Humans; Iatrogenic Disease; Infections; Methotrexate; Neoplasms; Pentoxifylline; Phosphodiesterase 4 Inhibitors; Phototherapy; Piperidines; Pyrimidines; Thalidomide | 2022 |
Two cases of Hailey-Hailey disease effectively treated with apremilast and a review of reported cases.
Topics: Adult; Calcium-Transporting ATPases; Female; Humans; Male; Mutation; Pemphigus, Benign Familial; Thalidomide | 2021 |
Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis.
Topics: Arthritis; Behcet Syndrome; Genitalia; Humans; Oral Ulcer; Skin Ulcer; Thalidomide; Ulcer | 2022 |
Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.
Topics: Adolescent; Biological Products; Drug Therapy, Combination; Exanthema; Humans; Psoriasis; Retrospective Studies; Thalidomide | 2022 |
Deucravacitinib for the Treatment of Psoriatic Disease.
Topics: Biological Factors; Double-Blind Method; Heterocyclic Compounds; Humans; Interferon Type I; Interleukin-12; Interleukin-17; Interleukin-23; Janus Kinase Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; TYK2 Kinase | 2022 |
Evolving utility of apremilast in dermatological disorders for off-label indications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Behcet Syndrome; Humans; Off-Label Use; Psoriasis; Thalidomide | 2022 |
Deucravacitinib in the treatment of psoriasis.
Topics: Chronic Disease; Humans; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide | 2023 |
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
Topics: Adult; Humans; Psoriasis; Skin; Thalidomide; Treatment Outcome | 2023 |
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Topics: Adult; Clinical Trials, Phase III as Topic; Humans; Psoriasis; Skin; Thalidomide; Treatment Outcome | 2023 |
82 trial(s) available for thalidomide and apremilast
| Article | Year |
|---|---|
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Biopsy, Needle; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidermis; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pilot Projects; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2008 |
Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
Topics: Administration, Oral; Adult; Carbon Radioisotopes; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Male; Mass Spectrometry; Middle Aged; Phosphodiesterase 4 Inhibitors; Radioactivity; Thalidomide; Time Factors; Tumor Necrosis Factor-alpha; Young Adult | 2011 |
Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
Topics: Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Sarcoidosis; Severity of Illness Index; Skin Diseases; Thalidomide; Treatment Outcome | 2012 |
A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Topics: Adult; Aged; Dermatitis, Allergic Contact; Dermatitis, Atopic; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Severity of Illness Index; Thalidomide; Treatment Outcome; Young Adult | 2012 |
A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
Topics: Adult; Cyclic AMP Response Element-Binding Protein; Dermatitis, Atopic; Female; Gene Expression Profiling; Humans; Interleukin-12; Macrophages; Male; Middle Aged; Monocytes; Nausea; Oligonucleotide Array Sequence Analysis; Phosphodiesterase 4 Inhibitors; Pilot Projects; Pruritus; Quality of Life; Severity of Illness Index; Signal Transduction; Thalidomide | 2012 |
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Quality of Life; Thalidomide; Treatment Outcome | 2012 |
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Psoriatic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Thalidomide; Treatment Outcome | 2012 |
An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.
Topics: Humans; Lichen Planus; Pilot Projects; Thalidomide | 2013 |
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone and Bones; Bone Morphogenetic Proteins; Disability Evaluation; Double-Blind Method; Female; Genetic Markers; Health Status; Humans; Male; Middle Aged; Osteoprotegerin; Phosphodiesterase 4 Inhibitors; Pilot Projects; RANK Ligand; Severity of Illness Index; Spondylitis, Ankylosing; Thalidomide; Treatment Outcome | 2013 |
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Placebos; Psoriasis; Severity of Illness Index; Thalidomide | 2013 |
Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
Topics: Adult; Aged; Diarrhea; Female; Headache; Humans; Intention to Treat Analysis; Lupus Erythematosus, Discoid; Male; Middle Aged; Nausea; Phosphodiesterase 4 Inhibitors; Pilot Projects; Severity of Illness Index; Statistics, Nonparametric; Thalidomide; Young Adult | 2012 |
Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Disability Evaluation; Fatigue; Female; Health Status; Humans; Male; Middle Aged; Pain Measurement; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Thalidomide; Treatment Outcome | 2013 |
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
Topics: Adult; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Quality Indicators, Health Care; Quality of Life; Self Report; Surveys and Questionnaires; Thalidomide; Treatment Outcome | 2013 |
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Follow-Up Studies; Humans; Inflammation; Leukocytes; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2013 |
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Treatment Outcome | 2014 |
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Carrier Proteins; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Ketoconazole; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Rifampin; Substrate Specificity; Thalidomide; Young Adult | 2014 |
Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Severity of Illness Index; Thalidomide; Treatment Outcome | 2015 |
Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Joints; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Severity of Illness Index; Thalidomide; Treatment Outcome | 2015 |
Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Behcet Syndrome; Double-Blind Method; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Oral Ulcer; Phosphodiesterase 4 Inhibitors; Thalidomide | 2015 |
The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biomarkers; Cytokines; Humans; Inflammation; Phosphodiesterase 4 Inhibitors; Placebos; Severity of Illness Index; Th1 Cells; Th17 Cells; Thalidomide; Treatment Outcome | 2015 |
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Topics: Administration, Oral; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide | 2015 |
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Topics: Administration, Oral; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome | 2015 |
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nail Diseases; Phosphodiesterase 4 Inhibitors; Psoriasis; Risk Assessment; Scalp Dermatoses; Severity of Illness Index; Thalidomide; Time Factors; Treatment Outcome | 2016 |
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Severity of Illness Index; Skin; Thalidomide; Treatment Outcome | 2016 |
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Phosphodiesterase 4 Inhibitors; Pruritus; Psoriasis; Quality of Life; Remission Induction; Severity of Illness Index; Surveys and Questionnaires; Thalidomide; Time Factors; Treatment Outcome | 2016 |
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical
Topics: Administration, Oral; Adult; Double-Blind Method; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide | 2016 |
The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Electrocardiography; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Thalidomide | 2016 |
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Double-Blind Method; Female; Humans; Male; Middle Aged; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Patient Reported Outcome Measures; Phosphodiesterase 4 Inhibitors; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Work Capacity Evaluation | 2017 |
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Double-Blind Method; Etanercept; Female; Headache; Humans; Male; Middle Aged; Nasopharyngitis; Nausea; Pain; Phosphodiesterase 4 Inhibitors; Pruritus; Psoriasis; Respiratory Tract Infections; Severity of Illness Index; Symptom Assessment; Tension-Type Headache; Thalidomide | 2017 |
Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.
Topics: Administration, Oral; Adult; Benchmarking; Body Surface Area; Dermatology; Female; Global Health; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide | 2017 |
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Incidence; Japan; Male; Middle Aged; Nasopharyngitis; Phosphodiesterase 4 Inhibitors; Placebos; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Female; Headache; Humans; Incidence; Male; Middle Aged; Nasopharyngitis; Nausea; Neoplasms; Psoriasis; Respiratory Tract Infections; Suicide, Attempted; Tension-Type Headache; Thalidomide; Time Factors | 2017 |
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Symptom Assessment; Thalidomide; United States | 2017 |
Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Humans; Middle Aged; Pilot Projects; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; Ultraviolet Therapy | 2017 |
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
Topics: Double-Blind Method; Efficiency; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Placebos; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Work | 2018 |
Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.
Topics: Body Surface Area; Humans; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2017 |
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Etanercept; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Placebos; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide | 2018 |
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; C-Reactive Protein; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Severity of Illness Index; Thalidomide; Treatment Outcome | 2018 |
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Factors; Diarrhea; Double-Blind Method; Female; Headache; Humans; Male; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Time Factors; Treatment Outcome | 2018 |
Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Epidermolysis Bullosa Simplex; Female; Humans; Infant; Infant, Newborn; Keratin-14; Keratin-5; Male; Middle Aged; Mutation; Pilot Projects; Retrospective Studies; Skin; Th17 Cells; Thalidomide; Treatment Outcome; Young Adult | 2019 |
Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosphate; Adipose Tissue; Administration, Intravaginal; Adolescent; Adsorption; Adult; Adverse Childhood Experiences; Age Distribution; Age Factors; Aged; Aged, 80 and over; Air Pollution, Indoor; Aldehyde Oxidase; Alginates; Alloys; alpha-Globins; Aluminum Hydroxide; Alveolar Bone Loss; Anaerobiosis; Anesthesia, General; Anesthetics; Animals; Anovulation; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bacillus cereus; Bacterial Typing Techniques; Bacteroidetes; Base Composition; Biocompatible Materials; Biofilms; Biological Availability; Biological Transport; Biosensing Techniques; Bipolar Disorder; Blood Glucose; Body Mass Index; Bone Regeneration; Boranes; Brachial Artery; Butyric Acid; Candida albicans; Carbon; Carcinoembryonic Antigen; Cell Differentiation; Cell Line, Tumor; Cell Respiration; Cell Survival; Cells, Cultured; Cerebrovascular Circulation; Charcoal; Child; Child Health; China; Chloride Channels; Chlorides; CHO Cells; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromium; Chronic Disease; Chronic Periodontitis; Circular Dichroism; Cities; Cohort Studies; Comamonadaceae; Comorbidity; Coronary Artery Disease; Corrosion; Cricetinae; Cricetulus; Cross Infection; Cross-Sectional Studies; Crowding; Culture Media; Cytokines; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diarylheptanoids; Diclofenac; Disability Evaluation; Diterpene Alkaloids; DNA; DNA Mutational Analysis; DNA, Bacterial; Drug Liberation; Drug Resistance, Multiple, Bacterial; Electrochemical Techniques; Electrodes; Electrolytes; Endothelium, Vascular; Enterococcus faecalis; Epithelial Cell Adhesion Molecule; Epithelial Cells; Erbium; Erythropoietin; Ethanol; Ethylenediamines; Fast Foods; Fatty Acids; Female; Fermentation; Ferric Compounds; Fibroblasts; Flavobacteriaceae; Fluorides; Fluorodeoxyglucose F18; Food Microbiology; Formaldehyde; Furaldehyde; Gamma Cameras; Gene Expression; Geologic Sediments; Glucose Tolerance Test; Glycated Hemoglobin; Glycolipids; Glycosylation; Gracilaria; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Guanine; Health Surveys; HeLa Cells; Hemoglobins, Abnormal; Hexosamines; High Fructose Corn Syrup; High-Intensity Interval Training; Hip Fractures; Hippocampus; HLA-B27 Antigen; Hospitalization; Housing; Humans; Hydrogen-Ion Concentration; Hydrolysis; Hydroxides; Hypercapnia; Hypertension; Hypocreales; Hypromellose Derivatives; Image Processing, Computer-Assisted; Incidence; Indole Alkaloids; Indonesia; Inflammation Mediators; Infrared Rays; Insulin Resistance; Intercalating Agents; Ion Transport; Ionophores; Japan; Kinetics; Kluyveromyces; Letrozole; Linear Models; Lipopolysaccharides; Liposomes; Liver; Lung Diseases; Magnesium Hydroxide; Magnetic Resonance Spectroscopy; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Microscopy, Electron, Transmission; Middle Aged; Mitochondria; Mitochondria, Muscle; Molecular Docking Simulation; Molecular Structure; Muscle, Skeletal; Mutant Proteins; Mutation; Mutation, Missense; Nanocomposites; Nanoparticles; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nucleic Acid Hybridization; Obesity; Occupational Exposure; Oceans and Seas; Odds Ratio; Organometallic Compounds; Osteogenesis; Ovulation Induction; Oxidation-Reduction; Particle Size; Periodontal Ligament; Permeability; Phaseolus; Phenotype; Philippines; Phosphatidylethanolamines; Phospholipids; Photochemical Processes; Phylogeny; Pichia; Pigmentation; Plant Extracts; Polycystic Ovary Syndrome; Polysaccharides; Postprandial Period; Pregnancy; Pregnancy Rate; Prevalence; Product Surveillance, Postmarketing; Progesterone; Progestins; Protein Engineering; Pseudomonas aeruginosa; Psoriasis; Public Facilities; Rats; Rats, Wistar; Receptors, Thyrotropin; Recombinant Proteins; Reproducibility of Results; Republic of Korea; Retrospective Studies; Rhodobacteraceae; Risk; Risk Assessment; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Saccharomyces cerevisiae; Salinity; Saliva; Seawater; Seaweed; Sensitivity and Specificity; Sequence Analysis, DNA; Sex Factors; Silver Compounds; Smokers; Social Class; Socioeconomic Factors; Soil Microbiology; Solubility; Soy Foods; Spectrometry, Mass, Electrospray Ionization; Spondylitis, Ankylosing; Staphylococcus aureus; Static Electricity; Steroids; Strontium; Sucrose; Surface Properties; Survival Rate; Sweden; Swine; Synapses; Synchrotrons; Tandem Mass Spectrometry; Tannins; Tea; Temperature; Terpenes; Thalidomide; Thermodynamics; Thiadiazoles; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy; Time Factors; Tissue Distribution; Titanium; Toilet Facilities; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Ubiquinone; Urinary Tract Infections; Vaginal Creams, Foams, and Jellies; Venezuela; Vitamin K 2; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Microbiology; Water Pollutants, Chemical; Whole Body Imaging; X-Ray Diffraction; Young Adult; Ytterbium; Yttrium; Yttrium Radioisotopes; Zinc Compounds | 2018 |
Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Etanercept; Female; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; United States | 2018 |
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Topics: Adult; Aged; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Middle Aged; Pilot Projects; Thalidomide; Young Adult | 2019 |
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers; Cystatins; Female; Hidradenitis Suppurativa; Humans; Interleukin-12; Interleukin-17; Male; Middle Aged; RNA, Messenger; S100A12 Protein; Thalidomide; Young Adult | 2019 |
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Hidradenitis Suppurativa; Humans; Male; Severity of Illness Index; Thalidomide; Treatment Outcome | 2019 |
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.
Topics: Administration, Oral; Adult; Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Atopic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; North America; Risk Assessment; Severity of Illness Index; Sex Factors; Thalidomide; Treatment Outcome | 2019 |
Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Gastrointestinal Diseases; Hidradenitis Suppurativa; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2019 |
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Double-Blind Method; Female; Humans; Male; Middle Aged; Thalidomide; Time; Treatment Outcome | 2019 |
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide | 2020 |
Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Behcet Syndrome; Double-Blind Method; Female; Humans; Male; Oral Ulcer; Phosphodiesterase 4 Inhibitors; Quality of Life; Thalidomide | 2019 |
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study.
Topics: Adipokines; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins; Cytokines; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; T-Lymphocyte Subsets; Thalidomide | 2019 |
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Severity of Illness Index; Thalidomide | 2020 |
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
Topics: Adult; Biological Therapy; Colitis, Ulcerative; Cyclic Nucleotide Phosphodiesterases, Type 4; Double-Blind Method; Humans; Remission Induction; Thalidomide; Treatment Outcome | 2020 |
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Gene Expression Regulation; Glycoproteins; Humans; Interleukin-17; Interleukin-6; Kallikreins; Proteomics; Psoriasis; Severity of Illness Index; Spondylitis, Ankylosing; Thalidomide; Treatment Outcome | 2020 |
Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Placebos; Prospective Studies; Severity of Illness Index; Skin Pigmentation; Thalidomide; Treatment Outcome; Ultraviolet Therapy; Vitiligo | 2020 |
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Psoriasis; Quality of Life; Scalp Dermatoses; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Psoriasis improvement and satisfaction in patients using a clobetasol spray and oral apremilast combination regimen: A pilot study.
Topics: Administration, Oral; Aerosols; Clobetasol; Drug Therapy, Combination; Female; Humans; Male; Patient Satisfaction; Phosphodiesterase 4 Inhibitors; Pilot Projects; Prospective Studies; Psoriasis; Thalidomide; Treatment Outcome | 2020 |
Evaluation of Patient-Reported Outcomes With Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Etanercept; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Patient Reported Outcome Measures; Psoriasis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Thalidomide; Treatment Outcome; United States | 2020 |
Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study.
Topics: Administration, Oral; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nail Diseases; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial.
Topics: Adult; Double-Blind Method; Humans; Japan; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pruritus; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome; Visual Analog Scale | 2020 |
The efficacy of in vivo administration of Apremilast on mesenchymal stem cells derived from psoriatic patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Mesenchymal Stem Cells; Middle Aged; Nitric Oxide Synthase Type II; Psoriasis; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2021 |
Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Diarrhea; Drug Combinations; Drug Therapy, Combination; Female; Headache; Humans; Male; Middle Aged; Nausea; Pilot Projects; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; Young Adult | 2020 |
Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
Topics: Administration, Oral; Adult; Animals; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Evaluation, Preclinical; Drugs, Investigational; Enzyme Assays; Female; Healthy Volunteers; Humans; Macaca mulatta; Male; Mice; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2021 |
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study.
Topics: Humans; Pilot Projects; Skin Pigmentation; Thalidomide; Treatment Outcome; Ultraviolet Therapy; Vitiligo | 2021 |
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis.
Topics: Double-Blind Method; Humans; Phosphodiesterase 4 Inhibitors; Severity of Illness Index; Spondylitis, Ankylosing; Thalidomide; Treatment Outcome | 2021 |
Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
Topics: Adult; Dermatologic Agents; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Psoriasis; Scalp; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Asian People; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Half-Life; Healthy Volunteers; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Republic of Korea; Thalidomide; Young Adult | 2021 |
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Topics: Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Diseases, Vesiculobullous; Thalidomide; Treatment Outcome | 2021 |
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Double-Blind Method; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Thalidomide | 2022 |
The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Topics: Adult; Cohort Studies; Cytokines; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrimidines; Severity of Illness Index; Skin; Thalidomide; Treatment Outcome; Young Adult | 2021 |
Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.
Topics: Adult; Female; Genitalia; Humans; Lichen Planus; Norway; Quality of Life; Randomized Controlled Trials as Topic; Thalidomide | 2021 |
Serum lactate dehydrogenase level as a possible predictor of treatment preference in psoriasis.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Oxygen Consumption; Phosphodiesterase 4 Inhibitors; Psoriasis; T-Lymphocytes; Thalidomide | 2021 |
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: A phase 1b clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatomyositis; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Double-Blind Method; Humans; Japan; Quality of Life; Thalidomide | 2022 |
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Enthesopathy; Humans; Joint Diseases; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Topics: Behcet Syndrome; Humans; Oral Ulcer; Pain; Quality of Life; Thalidomide | 2022 |
Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial.
Topics: Dermatomyositis; Female; Humans; Middle Aged; Severity of Illness Index; Skin; Thalidomide; Treatment Outcome | 2022 |
Preclinical and clinical evidence for suppression of alcohol intake by apremilast.
Topics: Alcohol Drinking; Alcoholism; Animals; Ethanol; Humans; Mice; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2023 |
346 other study(ies) available for thalidomide and apremilast
| Article | Year |
|---|---|
10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Evaluation, Preclinical; Humans; JNK Mitogen-Activated Protein Kinases; Lupus Erythematosus, Systemic; Nanotechnology; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Receptors, Chemokine; Technology, Pharmaceutical; Thalidomide | 2006 |
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
Topics: Administration, Oral; Animals; Drug Discovery; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rats; Stereoisomerism; Structure-Activity Relationship; Thalidomide; Tumor Necrosis Factor-alpha | 2009 |
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Topics: Administration, Oral; Adult; Animals; Anti-Inflammatory Agents; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Enterotoxins; Gene Expression Regulation; Humans; Inflammation Mediators; Keratinocytes; Killer Cells, Natural; Leukocytes, Mononuclear; Lipopolysaccharides; Mice; Mice, SCID; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Psoriasis; RNA, Messenger; Severity of Illness Index; Skin; Skin Transplantation; Thalidomide; Time Factors; Transplantation, Heterologous; U937 Cells; Ultraviolet Rays; Zymosan | 2010 |
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rolipram; Severity of Illness Index; Synovial Membrane; Thalidomide; Tumor Necrosis Factor-alpha | 2010 |
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Topics: Arthritis, Psoriatic; Cyclic AMP; Humans; Interleukins; Nitric Oxide Synthase Type II; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Tumor Necrosis Factor-alpha | 2012 |
Apremilast: a step forward in the treatment of psoriasis?
Topics: Female; Humans; Immunosuppressive Agents; Male; Psoriasis; Thalidomide | 2012 |
Therapeutics: Silencing psoriasis.
Topics: Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Dermatologic Agents; Humans; Interleukin-17; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Recombinant Fusion Proteins; Thalidomide; Ustekinumab | 2012 |
Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs.
Topics: Clinical Trials, Phase III as Topic; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Drug Approval; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2013 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis.
Topics: Arthritis, Psoriatic; Humans; Phosphodiesterase Inhibitors; Thalidomide | 2014 |
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Topics: Adaptive Immunity; Animals; B-Lymphocytes; Cell Line; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Models, Animal; Female; Ferrets; Humans; Immunity, Innate; Jurkat Cells; Lung Diseases; Male; Mice; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Protein Binding; T-Lymphocytes; Thalidomide; Vomiting | 2014 |
First PDE4 inhibitor for psoriasis hits the market but impact is uncertain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Approval; Drug Industry; Humans; Marketing of Health Services; Phosphodiesterase Inhibitors; Psoriasis; Thalidomide; Treatment Outcome; United States | 2014 |
First oral medication ok'd to fight psoriatic arthritis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Drug Approval; Humans; Thalidomide; United States; United States Food and Drug Administration | 2014 |
An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Rosacea; Thalidomide | 2014 |
Drug updates and approvals: 2014 in review.
Topics: Allergens; Benzhydryl Compounds; Benzyl Alcohols; Chlorobenzenes; Drug Approval; Dry Powder Inhalers; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Lactones; Nurse Practitioners; Phleum; Plant Extracts; Pollen; Pyrazoles; Pyridines; Pyrimidines; Quinuclidines; Thalidomide; United States; United States Food and Drug Administration | 2014 |
New biological treatments for psoriatic arthritis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Psoriatic; Clinical Trials as Topic; Humans; Immunologic Factors; Interleukin-17; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Rituximab; Thalidomide; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2014 |
The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo.
Topics: Alopecia Areata; Animals; Anti-Inflammatory Agents, Non-Steroidal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Ligands; Mice; Mice, SCID; NK Cell Lectin-Like Receptor Subfamily K; Phosphodiesterase 4 Inhibitors; Pilot Projects; Skin; Thalidomide | 2015 |
New drugs 2015, part 1.
Topics: Benzhydryl Compounds; Benzyl Alcohols; Chlorobenzenes; Dibenzazepines; Drug Approval; Estrogens, Conjugated (USP); Glucosides; Humans; Indoles; Nitriles; Pyridones; Pyrimidines; Quinuclidines; Thalidomide; United States; United States Food and Drug Administration | 2015 |
Behcet disease: A new therapeutic agent. [corrected].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Humans; Thalidomide | 2015 |
Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Humans; Male; Psoriasis; Retreatment; Thalidomide | 2015 |
The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressive Agents; Infliximab; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Psoriasis; Severity of Illness Index; Thalidomide; Ustekinumab; Young Adult | 2015 |
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.
Topics: Adenosine; Animals; Antirheumatic Agents; Blotting, Western; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cytokines; Gene Expression; Guanine Nucleotide Exchange Factors; Inflammation Mediators; Macrophages; Male; Methotrexate; Mice; Phenethylamines; Phosphodiesterase 4 Inhibitors; Receptor, Adenosine A2A; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thalidomide; Tumor Necrosis Factor-alpha | 2015 |
Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
Topics: Aged; Biopsy; Drug Resistance; Drug Substitution; Follow-Up Studies; Humans; Male; Phosphodiesterase 4 Inhibitors; Pityriasis Rubra Pilaris; Remission Induction; Skin; Thalidomide | 2016 |
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Humans; Molecular Targeted Therapy; Psoriasis; Signal Transduction; Thalidomide | 2016 |
Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Topics: Adapalene; Adult; Cell Differentiation; Cell Movement; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Dermis; Female; Gene Expression Regulation, Enzymologic; Humans; Immunohistochemistry; Immunoprecipitation; Inflammation; Inflammation Mediators; Isoenzymes; Leukocytes, Mononuclear; Male; Myofibroblasts; Psoriasis; Thalidomide | 2016 |
Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Combined Modality Therapy; Dermatologic Agents; Female; Humans; Male; Middle Aged; Phototherapy; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome; Young Adult | 2016 |
Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
Topics: Administration, Oral; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Nail Diseases; Phosphodiesterase 4 Inhibitors; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study.
Topics: Animals; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Limit of Detection; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry; Thalidomide | 2016 |
Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Humans; Male; Psoriasis; Thalidomide | 2016 |
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.
Topics: Acitretin; Biological Factors; Cyclosporine; Dermatology; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Psoriasis; Societies, Medical; Switzerland; Thalidomide | 2016 |
New Therapies for Psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dermatologic Agents; Dermatology; Humans; Psoriasis; Thalidomide; Treatment Outcome | 2016 |
Oral Lichen Planus Treated With Apremilast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Follow-Up Studies; Humans; Lichen Planus, Oral; Thalidomide; Treatment Outcome | 2016 |
Development of an Extended-Release Formulation for Apremilast and a Level A in Vitro-in Vivo Correlation Study in Beagle Dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Dogs; Drug Liberation; Tablets; Thalidomide | 2016 |
Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Dose-Response Relationship, Drug; Heart; Lipid Peroxidation; Male; MAP Kinase Signaling System; Myocardium; NF-kappa B; Oligopeptides; Oxidative Stress; Rats, Wistar; Thalidomide | 2016 |
Appearance of lentigines in psoriasis patients treated with apremilast.
Topics: Adult; Aged; Clinical Trials, Phase III as Topic; Female; Humans; Lentigo; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2016 |
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.
Topics: Adult; Arthritis, Psoriatic; Female; Humans; Male; Middle Aged; Nurse Practitioners; Phosphodiesterase 4 Inhibitors; Thalidomide | 2016 |
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.
Topics: Adolescent; Adult; Aged; Area Under Curve; Biotransformation; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Renal Insufficiency; Thalidomide | 2016 |
Safety evaluation of apremilast for the treatment of psoriasis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2017 |
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Topics: Animals; Bleomycin; Cell Differentiation; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Models, Animal; DNA Topoisomerases, Type I; Fibroblasts; Fibrosis; Gene Expression; Graft vs Host Disease; Humans; Interleukin-13; Interleukin-6; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; RNA, Messenger; Rolipram; Scleroderma, Systemic; Skin; Thalidomide; Transforming Growth Factor beta1; Transforming Growth Factor beta2 | 2017 |
[Apremilast: Beware of suicidal ideation and behaviour].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Depression; France; Humans; Prevalence; Psoriasis; Risk Factors; Suicidal Ideation; Thalidomide | 2017 |
Apremilast, beyond psoriasis as a therapeutic target.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Psoriasis; Thalidomide | 2017 |
Management of patients with psoriasis.
Topics: Acitretin; Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Disease Management; Emollients; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Thalidomide | 2017 |
Apremilast for treatment of recurrent erythema multiforme.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Erythema Multiforme; Female; Humans; Male; Mouth Diseases; Recurrence; Thalidomide; Young Adult | 2017 |
Resolution of psoriasis after tonsillectomy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Facial Dermatoses; Female; Glucocorticoids; Humans; Pharyngitis; Psoriasis; Recurrence; Remission Induction; Scalp Dermatoses; Streptococcal Infections; Thalidomide; Tonsillectomy; Tonsillitis; Treatment Failure; Ultraviolet Therapy; Young Adult | 2017 |
Solubility and thermodynamics of apremilast in different mono solvents: Determination, correlation and molecular interactions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Solubility; Solvents; Thalidomide; Thermodynamics | 2017 |
Apremilast and suicidality - a retrospective analysis of three large databases: the FAERS, EudraVigilance and a large single-centre US patient population.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Humans; Pharmacovigilance; Product Surveillance, Postmarketing; Psoriasis; Retrospective Studies; Risk Factors; Suicide; Thalidomide; United States; United States Food and Drug Administration | 2017 |
Apremilast for a psoriasis patient with HIV and hepatitis C.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Psoriasis; Thalidomide | 2017 |
Identification and characterization of process-related substances and degradation products in apremilast: Process optimization and degradation pathway elucidation.
Topics: Chromatography, Liquid; Drug Stability; Tandem Mass Spectrometry; Thalidomide | 2017 |
The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
Topics: Amino Sugars; Coculture Techniques; Cyclic AMP; Cytokines; Dendritic Cells; Humans; Immunologic Factors; Leukocytes, Mononuclear; Nuclear Receptor Subfamily 1, Group F, Member 3; Phosphodiesterase 4 Inhibitors; Psoriasis; T-Box Domain Proteins; Th1 Cells; Th17 Cells; Thalidomide; Tumor Necrosis Factor-alpha | 2017 |
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hidradenitis Suppurativa; Humans; Male; Middle Aged; Quality of Life; Sampling Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2017 |
Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
Topics: Administration, Oral; Chronic Disease; Dermatitis, Atopic; Dermatologic Agents; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Severity of Illness Index; Thalidomide | 2017 |
Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Dermatitis, Atopic; Eczema; Female; Humans; Male; Middle Aged; Severity of Illness Index; Thalidomide | 2017 |
Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Psoriasis; Severity of Illness Index; Thalidomide; Young Adult | 2017 |
Quality of life, treatment satisfaction and efficacy of non-biological systemic therapies in patients with plaque psoriasis: study protocol for a prospective observational study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Fumarates; Humans; Methotrexate; Patient Compliance; Patient Satisfaction; Personal Satisfaction; Pilot Projects; Prospective Studies; Psoriasis; Quality of Life; Thalidomide | 2017 |
Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins p21(ras); Thalidomide; Xenograft Model Antitumor Assays | 2017 |
Purpura Annularis Telangiectodes of Majocchi Associated With the Initiation and Rechallenge of Apremilast for Psoriasis Vulgaris.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Humans; Male; Middle Aged; Psoriasis; Purpura; Skin; Telangiectasis; Thalidomide | 2017 |
The Use of Apremilast to Treat Psoriasis During Deployment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Military Personnel; Psoriasis; Thalidomide; Treatment Outcome; United States; Warfare | 2017 |
Proximal Renal Tubular Acidosis (Fanconi Syndrome) Induced by Apremilast: A Case Report.
Topics: Acidosis; Acidosis, Renal Tubular; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Fanconi Syndrome; Humans; Hypokalemia; Male; Proteinuria; Thalidomide; Uric Acid | 2017 |
Improvement in the Axial Symptoms and Magnetic Resonance Imaging Findings With Apremilast in Psoriatic Arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Disease Progression; Humans; International Cooperation; Magnetic Resonance Imaging; Male; Radiography; Sacroiliac Joint; Sacroiliitis; Spine; Thalidomide | 2017 |
European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dermatologic Agents; Humans; Psoriasis; Thalidomide | 2017 |
Lack of efficacy of apremilast in 9 patients with severe alopecia areata.
Topics: Adolescent; Adult; Age Factors; Aged; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Needs Assessment; Retrospective Studies; Risk Assessment; Sampling Studies; Severity of Illness Index; Sex Factors; Thalidomide; Treatment Failure; Young Adult | 2017 |
Apremilast in psoriasis - a prospective real-world study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Body Weight; Diarrhea; Drug Substitution; Female; Headache; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Obesity; Prospective Studies; Psoriasis; Severity of Illness Index; Thalidomide; Time Factors; Young Adult | 2018 |
Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Consensus Development Conferences as Topic; Dermatologic Agents; Humans; Practice Guidelines as Topic; Psoriasis; Review Literature as Topic; Thalidomide | 2017 |
A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Canada; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide | 2018 |
Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Psoriasis; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Time Factors; Treatment Refusal | 2018 |
Successful treatment of SAPHO syndrome with apremilast.
Topics: Acquired Hyperostosis Syndrome; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance; Female; Humans; Thalidomide; Treatment Outcome; Young Adult | 2018 |
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Body Surface Area; Comorbidity; Cost of Illness; Cross-Sectional Studies; Fatigue; Female; Humans; Interleukin-12; Interleukin-17; Interleukin-23; Male; Middle Aged; Pain; Patient Reported Outcome Measures; Prospective Studies; Psoriasis; Quality of Life; Registries; Severity of Illness Index; Thalidomide; Tumor Necrosis Factor-alpha; United States | 2018 |
Otezla, Warts and All, Racks Up Sales and Eyes Blockbuster Status.
Topics: Administration, Oral; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; United States | 2017 |
Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Cohort Studies; Databases, Factual; Ethnicity; Female; Humans; Longitudinal Studies; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; United States | 2017 |
Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Thalidomide; Treatment Outcome | 2018 |
Cutaneous hyperpigmentation induced by apremilast.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Facial Dermatoses; Female; Follow-Up Studies; Humans; Hyperpigmentation; Psoriasis; Risk Assessment; Severity of Illness Index; Thalidomide | 2018 |
Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Failure | 2018 |
A case of severe pityriasis rubra pilaris with a dramatic response to apremilast.
Topics: Dermatologic Agents; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pityriasis Rubra Pilaris; Remission Induction; Thalidomide; Treatment Outcome | 2018 |
[Current and upcoming treatments of adult atopic dermatitis].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Ustekinumab | 2017 |
Rapid improvement of nail matrix psoriasis with apremilast: clinical and ultrasonographic assessment.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Middle Aged; Nail Diseases; Nails; Psoriasis; Thalidomide; Ultrasonography | 2018 |
Apremilast Alters Behavioral Responses to Ethanol in Mice: II. Increased Sedation, Intoxication, and Reduced Acute Functional Tolerance.
Topics: Alcoholic Intoxication; Animals; Behavior, Animal; Drug Interactions; Drug Tolerance; Ethanol; Female; Hypnotics and Sedatives; Male; Mice; Thalidomide | 2018 |
Apremilast Alters Behavioral Responses to Ethanol in Mice: I. Reduced Consumption and Preference.
Topics: Alcohol Drinking; Animals; Brain; Choice Behavior; Ethanol; Female; Food Preferences; Liver; Male; Mice; Motor Activity; Saccharin; Sucrose; Thalidomide | 2018 |
Persistent pruritus in psoriatic patients during administration of biologics.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Chemokine CCL17; Dermatologic Agents; Humans; Immunoglobulin E; Male; Middle Aged; Pruritus; Psoriasis; Severity of Illness Index; Th17 Cells; Th2 Cells; Thalidomide; Treatment Outcome; Ultraviolet Therapy | 2018 |
Drug survival of apremilast in patients treated for psoriasis in a real-world setting.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Psoriasis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Thalidomide; Time Factors; Treatment Outcome | 2018 |
[Apremilast withdrawals more frequent in standard practice than in clinical trials].
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Depression; Female; Humans; Male; Multicenter Studies as Topic; Psoriasis; Retrospective Studies; Safety-Based Drug Withdrawals; Sleep Wake Disorders; Thalidomide | 2018 |
A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Immunoglobulin G; Laminin; Male; Middle Aged; Pemphigoid, Bullous; Psoriasis; Thalidomide | 2018 |
Pharmacy costs of specialty medications for plaque psoriasis in the United States.
Topics: Adalimumab; Anti-Inflammatory Agents; Cost of Illness; Dermatologic Agents; Etanercept; Humans; Psoriasis; Thalidomide; Time Factors; United States; Ustekinumab | 2019 |
Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Time Factors; Treatment Outcome | 2018 |
Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Headache; Humans; Male; Middle Aged; Nausea; Psoriasis; Retrospective Studies; Thalidomide; Treatment Refusal | 2018 |
Early response to apremilast treatment in psoriatic arthritis: a real-life ultrasonographic follow-up study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Joints; Male; Middle Aged; Severity of Illness Index; Thalidomide; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2018 |
Comment on "Drug survival of apremilast for psoriasis in a real-world setting".
Topics: Humans; Psoriasis; Thalidomide | 2018 |
Three cases of palmoplantar pustulosis successfully treated with apremilast.
Topics: Administration, Oral; Female; Humans; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2019 |
Repy to: "Comment on 'Drug survival of apremilast for psoriasis in a real-world setting'".
Topics: Humans; Psoriasis; Thalidomide | 2018 |
Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast.
Topics: Humans; Lentigo; Male; Middle Aged; Phosphodiesterase Inhibitors; Psoriasis; Skin; Thalidomide | 2019 |
Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2018 |
A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Middle Aged; Phosphodiesterase 4 Inhibitors; Pityriasis Rubra Pilaris; Thalidomide | 2018 |
Complex Aphthae Treated With Apremilast.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Oral Ulcer; Psoriasis; Stomatitis, Aphthous; Thalidomide | 2020 |
Chronic tearing induced by apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Conjunctivitis; Cyclic Nucleotide Phosphodiesterases, Type 4; Female; Humans; Lacrimal Apparatus Diseases; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Tears; Thalidomide | 2018 |
Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study".
Topics: Humans; Psoriasis; Retrospective Studies; Thalidomide | 2018 |
Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways.
Topics: Animals; Apoptosis; Cardiotoxicity; Caspase 3; Catalase; Dose-Response Relationship, Drug; Doxorubicin; Glutathione; Glutathione Reductase; Inflammation; Male; Malondialdehyde; Myocardium; NF-kappa B; Oxidative Stress; Rats; RNA, Messenger; Signal Transduction; Thalidomide | 2018 |
Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Headache; Humans; Long-Term Care; Male; Middle Aged; Nausea; Psoriasis; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome; Weight Loss | 2019 |
Real-world use of apremilast for patients with psoriasis in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Headache; Humans; Japan; Male; Middle Aged; Nausea; Phosphodiesterase 4 Inhibitors; Pragmatic Clinical Trials as Topic; Psoriasis; Severity of Illness Index; Skin; Thalidomide; Treatment Outcome; Vomiting | 2018 |
Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Diarrhea; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2019 |
Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Female; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Nail Diseases; Psoriasis; Thalidomide; Tomography, Optical Coherence; Treatment Outcome | 2019 |
Improvement of alopecia areata with apremilast.
Topics: Alopecia Areata; Female; Humans; Middle Aged; Off-Label Use; Phosphodiesterase 4 Inhibitors; Thalidomide | 2019 |
Treatment of Severe Hailey-Hailey Disease With Apremilast.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pemphigus, Benign Familial; Severity of Illness Index; Skin; Thalidomide | 2018 |
A promising new treatment for SAPHO syndrome that deserves further studies.
Topics: Acquired Hyperostosis Syndrome; Humans; Thalidomide | 2018 |
Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatologists; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Psoriasis; Surveys and Questionnaires; Thalidomide; Treatment Outcome | 2019 |
Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; HIV Infections; Humans; Male; Middle Aged; Psoriasis; Remission Induction; Thalidomide; Treatment Outcome | 2018 |
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Female; Health Care Costs; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies; Thalidomide; United States | 2019 |
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Topics: Acitretin; Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Esters; Female; Fumarates; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome | 2019 |
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies; Thalidomide | 2019 |
Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Interleukin-10; Lipid Peroxidation; Male; Multiple Myeloma; NF-kappa B; Oligopeptides; Peroxidase; Rats; Rats, Inbred Strains; Thalidomide; Tumor Necrosis Factor-alpha; Vascular System Injuries | 2019 |
Psoriasis vulgaris associated with systemic lupus erythematosus successfully treated with apremilast.
Topics: Administration, Oral; Adult; Antibodies, Antinuclear; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Systemic; Phosphodiesterase 4 Inhibitors; Prednisolone; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2019 |
Lentigines within fixed drug eruption: reply to 'Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast'.
Topics: Adult; Dermoscopy; Drug Eruptions; Exanthema; Female; Humans; Hyperpigmentation; Inflammation; Lentigo; Phosphodiesterase Inhibitors; Psoriasis; Thalidomide; Ultraviolet Rays | 2019 |
Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Behcet Syndrome; Diagnosis, Differential; Drug Administration Schedule; Female; Humans; Middle Aged; Stomatitis, Aphthous; Thalidomide | 2018 |
Apremilast as a new treatment option for Acrodermatitis continua of Hallopeau.
Topics: Acrodermatitis; Aged; Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Thalidomide | 2019 |
Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis.
Topics: Administration, Oral; Biopsy; Bone Marrow Transplantation; Chronic Disease; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Skin; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2019 |
Successful treatment of psoriatic arthritis with apremilast in a mixed connective tissue disease patient.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Male; Mixed Connective Tissue Disease; Thalidomide; Treatment Outcome | 2020 |
Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Female; Health Expenditures; Humans; Insurance Claim Review; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Propensity Score; Psoriasis; Retrospective Studies; Thalidomide | 2019 |
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment.
Topics: Aged; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Creatinine; Electrocardiography; Female; Heart Failure; Humans; Incidental Findings; Psoriasis; Renal Insufficiency, Chronic; Thalidomide | 2019 |
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Hepatitis B; HIV Infections; Humans; Male; Thalidomide; Treatment Outcome | 2019 |
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Exfoliative; Humans; Male; Middle Aged; Pruritus; Psoriasis; Symptom Flare Up; Thalidomide; Treatment Outcome | 2019 |
Potential therapeutic targeting of inflammation in epidermolysis bullosa simplex.
Topics: Epidermolysis Bullosa Simplex; Humans; Inflammation; Mutation; Thalidomide | 2019 |
A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Thalidomide; Treatment Outcome; United Kingdom | 2019 |
Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Immunological; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Psoriasis; Rituximab; Thalidomide; Treatment Outcome | 2019 |
Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Nivolumab; Psoriasis; Thalidomide | 2019 |
Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast.
Topics: Dermatomyositis; Female; Humans; Immunomodulating Agents; Immunosuppressive Agents; Pruritus; Scalp; Thalidomide | 2021 |
Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats.
Topics: Animals; Calorimetry, Differential Scanning; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Kinetics; Male; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Rats, Wistar; Spectroscopy, Fourier Transform Infrared; Static Electricity; Thalidomide; X-Ray Diffraction | 2019 |
Severe bitter taste associated with apremilast.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Male; Psoriasis; Taste Perception; Thalidomide | 2019 |
Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Topics: Animals; Caco-2 Cells; CD4-Positive T-Lymphocytes; Colitis, Ulcerative; Colon; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Humans; Immunity, Mucosal; Intestinal Mucosa; Isoenzymes; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Phosphodiesterase 4 Inhibitors; Protein Kinases; RAW 264.7 Cells; Signal Transduction; Thalidomide | 2019 |
Healing of Mucocutaneous Lesions With Apremilast in Behçet Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Humans; Thalidomide | 2020 |
Chronic hand eczema and hepatogenic pruritus with good response to apremilast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Eczema; Hand Dermatoses; Humans; Male; Pruritus; Thalidomide; Treatment Outcome | 2019 |
Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
Topics: Adalimumab; Carnosine; Databases, Genetic; Databases, Pharmaceutical; Drug Repositioning; Etanercept; Gene Ontology; Gene Regulatory Networks; Genetic Association Studies; Glucosamine; Humans; Immunosuppressive Agents; Myasthenia Gravis; Organometallic Compounds; Pharmacogenomic Testing; Thalidomide; Zinc Compounds | 2019 |
Favorable response to apremilast in a patient with refractory psoriasis verrucosa.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Drug Resistance; Humans; Male; Psoriasis; Severity of Illness Index; Skin; Thalidomide; Treatment Outcome; Warts | 2019 |
Apremilast is effective in controlling the progression of adult vitiligo: A case series.
Topics: Adult; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Thalidomide; Vitiligo | 2019 |
Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy
Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Humans; Male; Patient Satisfaction; Pilot Projects; Psoriasis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Thalidomide; Treatment Outcome; Young Adult | 2019 |
Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Female; Humans; Male; Middle Aged; Neoplasms; Psoriasis; Retrospective Studies; Thalidomide; Treatment Outcome | 2019 |
Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Methotrexate; Middle Aged; National Health Programs; Psoriasis; Thalidomide | 2020 |
Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
Topics: Acrodermatitis; Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Middle Aged; Nail Diseases; Thalidomide; Treatment Outcome | 2019 |
Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2019 |
Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Female; Health Expenditures; Humans; Insurance Claim Review; Male; Medication Adherence; Middle Aged; Retrospective Studies; Thalidomide | 2019 |
Psoriasis treatment patterns: a retrospective claims study.
Topics: Adult; Aged; Biological Products; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Psoriasis; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2019 |
Successful treatment of acrodermatitis continua of Hallopeau with apremilast.
Topics: Acrodermatitis; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Fingers; Humans; Male; Middle Aged; Osteolysis; Radiography; Skin; Thalidomide; Treatment Outcome | 2019 |
Drug survival of apremilast in a real-world setting.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Japan; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Retrospective Studies; Severity of Illness Index; Sex Factors; Thalidomide; Time Factors; Treatment Outcome; Young Adult | 2019 |
Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; B-Lymphocytes, Regulatory; Biomarkers; Female; Flow Cytometry; Humans; Immunity, Innate; Interleukin-10; Lymphocyte Count; Male; Middle Aged; Psoriasis; T-Lymphocytes; Thalidomide | 2019 |
Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalidomide | 2020 |
Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; HIV Infections; Humans; Male; Middle Aged; Phototherapy; Psoriasis; Thalidomide | 2019 |
Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata.
Topics: Alopecia Areata; Animals; Mice; Piperidines; Pyrimidines; Pyrroles; Thalidomide | 2020 |
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Mouth Mucosa; Oral Ulcer; Prospective Studies; Quality of Life; Recurrence; Thalidomide; Time Factors; Treatment Outcome | 2020 |
Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical setting.
Topics: Adult; Aged; Clinical Decision-Making; Cross-Sectional Studies; Dermatologic Agents; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Thalidomide | 2019 |
Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Female; Humans; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Thalidomide; Ultrasonography | 2019 |
Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Scalp psoriasis in a haemodialysis patient successfully treated with a half-dose of apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Middle Aged; Psoriasis; Remission Induction; Renal Dialysis; Scalp Dermatoses; Thalidomide | 2019 |
Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Drug Therapy, Combination; Female; Humans; Male; Patient Reported Outcome Measures; Pityriasis Rubra Pilaris; Prognosis; Quality of Life; Surveys and Questionnaires; Thalidomide; Treatment Outcome | 2019 |
Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Mouth Mucosa; Thalidomide; Treatment Outcome | 2019 |
Apremilast does not appear to outlast methotrexate.
Topics: Humans; Methotrexate; National Health Programs; Psoriasis; Thalidomide | 2020 |
Complex methodology for rational design of Apremilast-benzoic acid co-crystallization process.
Topics: Benzoic Acid; Crystallization; Solubility; Solvents; Thalidomide; Thermodynamics | 2019 |
Steroid-resistant alopecia totalis in a child successfully treated with oral apremilast and platelet-rich plasma therapy.
Topics: Administration, Oral; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Child; Combined Modality Therapy; Humans; Male; Platelet-Rich Plasma; Thalidomide | 2019 |
One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance, Multiple; Hidradenitis Suppurativa; Humans; Male; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome | 2019 |
Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
Topics: Adult; Age Factors; Arthritis, Psoriatic; Biological Products; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Psoriasis; Quality of Life; Registries; Risk Assessment; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Thalidomide; Treatment Outcome | 2019 |
Real-world experiences of apremilast in clinics for Japanese patients with psoriasis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Female; Humans; Male; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome; Young Adult | 2019 |
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Topics: Adult; Animals; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Gene Expression; Healthy Volunteers; Humans; Interleukin-17; Interleukin-4; Keratinocytes; Mice; Mice, Inbred BALB C; Phosphodiesterase 4 Inhibitors; Primary Cell Culture; Protein Isoforms; Thalidomide | 2019 |
Apremilast and psoriasis in the real world: A retrospective case series.
Topics: Female; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies; Thalidomide; Treatment Outcome | 2020 |
New therapeutics for leprosy.
Topics: Erythema Nodosum; Humans; Leprosy; Thalidomide | 2020 |
Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
Topics: Alopecia Areata; Humans; Male; Phosphodiesterase 4 Inhibitors; Severity of Illness Index; Thalidomide; Treatment Outcome; Young Adult | 2019 |
Apremilast for the treatment of oral aphthae in Behçet disease.
Topics: Administration, Oral; Behcet Syndrome; Humans; Oral Ulcer; Stomatitis, Aphthous; Thalidomide | 2020 |
Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biosimilar Pharmaceuticals; Cost-Benefit Analysis; Female; Germany; Humans; Male; Middle Aged; Thalidomide | 2020 |
Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance; Female; Humans; Male; Middle Aged; Retrospective Studies; Stomatitis, Aphthous; Thalidomide | 2019 |
Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
Topics: Adalimumab; Adult; Databases, Factual; Dermatologic Agents; Etanercept; Female; Health Care Costs; Humans; Male; Medication Adherence; Middle Aged; Psoriasis; Retrospective Studies; Thalidomide; Treatment Outcome; Ustekinumab | 2021 |
A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Budgets; Cost-Benefit Analysis; Humans; Italy; Markov Chains; Quality of Life; Surveys and Questionnaires; Thalidomide | 2020 |
A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Drug Costs; Humans; Italy; Middle Aged; Psoriasis; Quality of Life; Quality-Adjusted Life Years; State Medicine; Thalidomide | 2020 |
Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Dermatologic Agents; Diarrhea; Drug Therapy, Combination; Drug Tolerance; Humans; Male; Middle Aged; Nausea; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Weight Loss | 2020 |
Apremilast in Psoriasis.
Topics: Humans; Psoriasis; Thalidomide | 2020 |
Successful treatment of pustulotic arthro-osteitis with apremilast: a case report with follow-up MRI.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Osteitis; Psoriasis; Remission Induction; Syndrome; Thalidomide | 2019 |
Successful treatment of refractory Hailey-Hailey disease with apremilast.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Pemphigus, Benign Familial; Phosphodiesterase 4 Inhibitors; Remission Induction; Thalidomide | 2020 |
Refractory palmoplantar pustulosis succesfully treated with apremilast.
Topics: Arthritis, Psoriatic; Humans; Psoriasis; Skin Diseases, Vesiculobullous; Thalidomide | 2020 |
The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Anxiety; Arthritis, Psoriatic; Biological Products; Cohort Studies; Depression; Humans; Psoriasis; Thalidomide; United States | 2020 |
Effects of apremilast on pustulotic arthro-osteitis in a real-world setting: Report of five cases.
Topics: Arthritis; Humans; Osteitis; Psoriasis; Thalidomide | 2020 |
Improvement of recalcitrant Sneddon-Wilkinson disease with apremilast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Skin Diseases, Vesiculobullous; Thalidomide | 2020 |
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
Topics: Colitis, Ulcerative; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Psoriasis; Thalidomide | 2020 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Topics: Acitretin; Cyclosporine; Drug Monitoring; Humans; Methotrexate; Piperidines; Psoriasis; Pyrimidines; Thalidomide | 2020 |
Combination of dermabrasion and Apremilast for Hailey-Hailey disease.
Topics: Dermabrasion; Humans; Pemphigus, Benign Familial; Thalidomide | 2021 |
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Female; Health Care Costs; Humans; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Thalidomide; United States | 2020 |
Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemokines; Female; Humans; Male; Middle Aged; Pilot Projects; Proof of Concept Study; Prurigo; Severity of Illness Index; Thalidomide; Treatment Failure; Visual Analog Scale | 2020 |
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel.
Topics: Administration, Oral; Aged; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Combinations; Drug Resistance; Female; Gels; Humans; Male; Middle Aged; Nail Diseases; Ointments; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Apremilast in benign chronic pemphigus (Hailey-Hailey disease).
Topics: Adult; Chronic Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pemphigus, Benign Familial; Phosphodiesterase 4 Inhibitors; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database.
Topics: Age Factors; Aged; Antirheumatic Agents; Biological Products; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Product Surveillance, Postmarketing; Psoriasis; Risk Factors; Stroke; Thalidomide; United States | 2020 |
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers.
Topics: Aged; Aged, 80 and over; Arthritis, Psoriatic; Biomarkers; Comorbidity; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Treatment Outcome | 2020 |
Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast.
Topics: Drug Carriers; Drug Liberation; Humans; Lipids; Nanoparticles; Thalidomide | 2020 |
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Topics: Adult; Humans; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Europe; Humans; Psoriasis; Quality of Life; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Long-term efficacy and safety of apremilast in psoriatic arthritis: Focus on skin manifestations and special populations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Italy; Psoriasis; Thalidomide; Treatment Outcome | 2020 |
A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis and SAMPUS.
Topics: Hidradenitis Suppurativa; Humans; Psoriasis; Thalidomide | 2020 |
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Crohn Disease; Drug Therapy, Combination; Humans; Male; Pyoderma Gangrenosum; Thalidomide; Treatment Outcome | 2020 |
Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biomarkers, Pharmacological; CD40 Antigens; CD40 Ligand; Female; Humans; Male; Mice; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Signal Transduction; Thalidomide | 2020 |
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Care; Dermatitis, Exfoliative; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Psoriasis; SARS-CoV-2; Thalidomide | 2020 |
Apremilast to treat oral ulcers in Behçet syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Humans; Oral Ulcer; Thalidomide | 2020 |
Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice.
Topics: Humans; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide | 2020 |
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Humans; Opportunistic Infections; Pandemics; Pneumonia, Viral; Psoriasis; SARS-CoV-2; Thalidomide | 2020 |
Recurrent generalized pustular psoriasis possibly triggered by apremilast.
Topics: Acute Disease; Humans; Psoriasis; Skin Diseases, Vesiculobullous; Thalidomide | 2020 |
Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.
Topics: Arthritis, Psoriatic; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Care; Humans; Infections; Oligodendroglioma; Pandemics; Pneumonia, Viral; SARS-CoV-2; Thalidomide | 2020 |
Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; Humans; Psoriasis; Rituximab; Thalidomide | 2021 |
Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Psoriasis; SARS-CoV-2; Thalidomide | 2020 |
The Search for a Uniformly Effective Treatment in Patients With Lupus Miliaris Disseminatus Faciei.
Topics: Administration, Oral; Adult; Facial Dermatoses; Granuloma; Humans; Male; Phosphodiesterase 4 Inhibitors; Severity of Illness Index; Thalidomide; Treatment Outcome; Young Adult | 2020 |
Apremilast for the off-label treatment of lichenoid and interface dermatoses.
Topics: Aged; Female; Humans; Lichenoid Eruptions; Middle Aged; Off-Label Use; Phosphodiesterase 4 Inhibitors; Retrospective Studies; Thalidomide; Young Adult | 2020 |
Successful use of apremilast as a steroid-sparing agent in chronic actinic dermatitis.
Topics: Chronic Disease; Humans; Photosensitivity Disorders; Steroids; Thalidomide | 2020 |
Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Exanthema; Humans; Male; Psoriasis; Thalidomide; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Novel nanocrystal-based formulations of apremilast for improved topical delivery.
Topics: Animals; Nanoparticles; Particle Size; Skin; Skin Absorption; Solubility; Swine; Thalidomide | 2021 |
COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; COVID-19; Female; Humans; Immunosuppressive Agents; Infliximab; Male; Middle Aged; Psoriasis; Spain; Thalidomide | 2020 |
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Factors; Clinical Decision-Making; Comorbidity; COVID-19; Cytokine Release Syndrome; Dermatology; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Patient Selection; Practice Guidelines as Topic; Psoriasis; Risk Assessment; Risk Factors; SARS-CoV-2; Societies, Medical; Thalidomide; Withholding Treatment | 2021 |
Apremilast-induced photosensitivity confirmed by photobiological study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Middle Aged; Photosensitivity Disorders; Thalidomide | 2021 |
Topics: Anti-Inflammatory Agents; Behcet Syndrome; Diagnosis, Differential; DNA Mutational Analysis; France; Humans; Immunogenetic Phenomena; Immunosuppressive Agents; Internal Medicine; Practice Guidelines as Topic; Societies, Medical; Thalidomide | 2020 |
Photosensitivity during apremilast treatment in patients with palmoplantar psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
Topics: Administration, Oral; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Medical Records; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology.
Topics: Humans; Prospective Studies; Thalidomide; Treatment Outcome; Ultraviolet Therapy; Vitiligo | 2020 |
Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit.
Topics: Humans; Nail Diseases; Nails; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Apremilast interferes with the TGFβ1-induced transition of human skin fibroblasts into profibrotic myofibroblasts: in vitro study.
Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cells, Cultured; Collagen Type I; Female; Fibroblasts; Fibronectins; Humans; Middle Aged; Myofibroblasts; Skin; Thalidomide; Transforming Growth Factor beta1 | 2020 |
Apremilast regulates acute effects of ethanol and other GABAergic drugs via protein kinase A-dependent signaling.
Topics: Animals; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Ethanol; Female; GABA Agonists; GABA Modulators; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Receptors, GABA-A; Reflex, Righting; Signal Transduction; Thalidomide; Xenopus laevis | 2020 |
Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Factors; Female; Humans; Male; Middle Aged; Pharmaceutical Preparations; Prospective Studies; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide | 2020 |
Anti-inflammatory capacity of Apremilast in human chondrocytes is dependent on SOX-9.
Topics: Aggrecans; Anti-Inflammatory Agents; Cell Line; Chondrocytes; Collagen Type II; Collagen Type X; Down-Regulation; Humans; Interleukin-1alpha; SOX9 Transcription Factor; Thalidomide; Up-Regulation | 2020 |
Apremilast in patients with history of malignancy: a real-life, single-center experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Neoplasms; Psoriasis; Thalidomide | 2021 |
[Apremilast in the treatment of palmoplantar pustulosis : A case series].
Topics: Exanthema; Humans; Psoriasis; Quality of Life; Thalidomide | 2021 |
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Duration of Therapy; Female; Follow-Up Studies; Hidradenitis Suppurativa; Humans; Middle Aged; Thalidomide; Time Factors; Treatment Outcome; Young Adult | 2021 |
Multidisciplinary Management of the Adverse Effects of Apremilast.
Topics: Combined Modality Therapy; Diarrhea; Disease Management; Headache; Humans; Nausea; Patient Care Team; Phosphodiesterase 4 Inhibitors; Practice Guidelines as Topic; Psoriasis; Thalidomide | 2021 |
Apremilast and systemic retinoid combination treatment for moderate to severe palmoplantar psoriasis.
Topics: Dermatologic Agents; Drug Therapy, Combination; Humans; Male; Middle Aged; Psoriasis; Retinoids; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Erythema nodosum leprosum successfully treated with apremilast: more effective and safer than classic treatments?
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalidomide | 2021 |
Apremilast in orofacial granulomatosis-A report of five cases.
Topics: Crohn Disease; Granulomatosis, Orofacial; Humans; Thalidomide | 2020 |
Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
Topics: Adult; Behcet Syndrome; Colchicine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Oral Ulcer; Prednisolone; Prospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2021 |
Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.
Topics: Aminopyridines; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cyclic AMP; Cyclopropanes; Down-Regulation; Humans; Inflammation Mediators; Interleukin-18; Interleukin-1alpha; Interleukin-8; Keratinocytes; MAP Kinase Signaling System; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Tumor Necrosis Factor-alpha | 2020 |
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic.
Topics: Adult; Antibodies, Monoclonal, Humanized; COVID-19; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Methotrexate; Prednisone; Psoriasis; SARS-CoV-2; Thalidomide | 2020 |
The Effects of Apremilast Therapy on Deployability in Active Duty US Army Soldiers With Plaque Psoriasis and Psoriatic Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Military Personnel; Psoriasis; Thalidomide | 2021 |
Use of Apremilast in Patients With Psoriatic Arthritis During the COVID-19 Pandemic: Comment on the Article by Mikuls et al.
Topics: Adult; Arthritis, Psoriatic; COVID-19; Humans; Pandemics; Rheumatic Diseases; Rheumatology; SARS-CoV-2; Thalidomide; United States | 2021 |
The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Biological Factors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Risk Factors; Stroke; Thalidomide | 2021 |
Reply.
Topics: Colitis, Ulcerative; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Thalidomide | 2020 |
Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Drug Therapy, Combination; Humans; Methotrexate; Registries; Spondylarthritis; Thalidomide; Treatment Outcome | 2021 |
Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris.
Topics: Drug Resistance; Female; Humans; Middle Aged; Pemphigus; Phosphodiesterase 4 Inhibitors; Thalidomide | 2020 |
Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?
Topics: Adrenal Cortex Hormones; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; COVID-19 Drug Treatment; Cyclopropanes; Cytokine Release Syndrome; Cytokines; Humans; Immune System; Immunity, Innate; Inflammation; Models, Theoretical; Phosphodiesterase 4 Inhibitors; Risk; Steroids; Thalidomide | 2020 |
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Topics: Acitretin; Aged; Biological Products; Dermatologic Agents; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Glucocorticoids; Humans; Immune Checkpoint Inhibitors; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Apremilast Regulates the Teff/Treg Balance to Ameliorate Uveitis
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; CD4-Positive T-Lymphocytes; Disease Models, Animal; Female; Forkhead Box Protein O1; Inflammation; Mice; Mice, Inbred C57BL; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; T-Lymphocytes, Regulatory; Thalidomide; Uveitis | 2020 |
Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Melanoma; Nivolumab; Psoriasis; Severity of Illness Index; Thalidomide | 2021 |
Apremilast prevents IL‑17‑induced cellular senescence in ATDC5 chondrocytes mediated by SIRT1.
Topics: Cell Line; Cellular Senescence; Chondrocytes; Humans; Interleukin-17; Sirtuin 1; Thalidomide | 2021 |
Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study.
Topics: Humans; Pilot Projects; Psoriasis; Retrospective Studies; Thalidomide | 2021 |
Apremilast in treatment of palmoplantar pustulosis - a case series.
Topics: Exanthema; Humans; Psoriasis; Skin Diseases, Vesiculobullous; Thalidomide | 2021 |
Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Humans; Pharmaceutical Preparations; Psoriasis; Thalidomide; Treatment Outcome | 2021 |
Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis.
Topics: Adult; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Fees, Pharmaceutical; Female; Health Care Costs; Hospitalization; Humans; Male; Medication Adherence; Middle Aged; Psoriasis; Thalidomide | 2021 |
Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Behcet Syndrome; Cohort Studies; Colchicine; Drug Combinations; Female; France; Humans; Male; Middle Aged; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Place of apremilast in the real-life treatment of patients with plaque psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Simultaneous Estimation of Apremilast and Betamethasone Dipropionate in Microsponge-Based Topical Formulation using a Stability Indicating RP-HPLC Method: A Quality-by-Design Approach.
Topics: Betamethasone; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Thalidomide | 2021 |
Mycobacterium bovis infection under apremilast in Behçet's syndrome.
Topics: Antitubercular Agents; Behcet Syndrome; Female; Humans; Middle Aged; Mycobacterium bovis; Phosphodiesterase 4 Inhibitors; Thalidomide; Tuberculosis | 2021 |
Long-term remission of severe nail psoriasis after discontinuation of apremilast in a colorectal cancer survivor.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Psoriasis; Severity of Illness Index; Survivors; Thalidomide; Treatment Outcome | 2021 |
Apremilast inhibits inflammatory osteoclastogenesis.
Topics: Adult; Aged; Arthritis, Psoriatic; Case-Control Studies; Cytokines; Drug Evaluation, Preclinical; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Osteogenesis; Phosphodiesterase 4 Inhibitors; Primary Cell Culture; Thalidomide | 2021 |
Is apremilast for psoriasis as effective and safe as reported in clinical trials? Five-year experience from a Greek tertiary hospital: long-term real-life efficacy and safety of apremilast in Greece.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Drug Administration Schedule; Female; Greece; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
The Protective Effects of Apremilast Against Oxygen-Glucose Deprivation/Reperfusion (OGD/R)-Induced Inflammation and Apoptosis in Astroglia Mediated by CREB/BDNF.
Topics: Animals; Apoptosis; Astrocytes; Brain-Derived Neurotrophic Factor; Cell Hypoxia; Cyclic AMP Response Element-Binding Protein; Dose-Response Relationship, Drug; Glucose; Neuroprotective Agents; Phosphodiesterase 4 Inhibitors; Rats; Thalidomide | 2021 |
Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells.
Topics: Animals; Blotting, Western; Cyclic Nucleotide Phosphodiesterases, Type 4; Female; Fibrosis; Flow Cytometry; Macrophages; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Real-Time Polymerase Chain Reaction; Skin; T-Lymphocytes; Thalidomide | 2022 |
Cycling or swap biologics and small molecules in psoriatic arthritis: Observations from a real-life single center cohort.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Cluster Analysis; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrimidines; Thalidomide; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2021 |
Beneficial Impact of Apremilast on Palmoplantar Keratodermas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Keratoderma, Palmoplantar; Psoriasis; Thalidomide | 2021 |
Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability.
Topics: Animals; Biological Availability; Calorimetry, Differential Scanning; Dosage Forms; Phosphodiesterase 4 Inhibitors; Povidone; Powder Diffraction; Rats; Solubility; Spectroscopy, Fourier Transform Infrared; Thalidomide; Vitamin E | 2021 |
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; COVID-19; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Risk Factors; Thalidomide | 2021 |
COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.
Topics: Administration, Oral; Adult; Aged; COVID-19; COVID-19 Vaccines; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Phosphodiesterase 4 Inhibitors; Psoriasis; SARS-CoV-2; Symptom Flare Up; Thalidomide | 2021 |
Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Topics: Adult; Biological Products; Female; Greece; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study.
Topics: Adult; Humans; Longitudinal Studies; Male; Psoriasis; Severity of Illness Index; Thalidomide | 2021 |
Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.
Topics: Adult; Arthritis, Psoriatic; Body Fat Distribution; Cardiometabolic Risk Factors; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Psoriasis; Thalidomide; Weight Loss | 2022 |
Directed evolution of an amine transaminase for the synthesis of an Apremilast intermediate via kinetic resolution.
Topics: Amines; Biocatalysis; Kinetics; Molecular Structure; Thalidomide; Transaminases; Vibrio | 2021 |
Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.
Topics: Arthritis, Psoriatic; Biological Products; Humans; Retrospective Studies; Thalidomide | 2021 |
Design and dermatokinetic evaluation of Apremilast loaded nanostructured lipid carriers embedded gel for topical delivery: A potential approach for improved permeation and prolong skin deposition.
Topics: Drug Carriers; Drug Liberation; Lipids; Nanostructures; Particle Size; Skin; Thalidomide | 2021 |
A novel combination treatment with apremilast and tumor necrosis factor inhibitor for a patient with refractory intestinal Behcet's disease.
Topics: Behcet Syndrome; Humans; Intestinal Diseases; Thalidomide; Tumor Necrosis Factor Inhibitors | 2022 |
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Topics: Animals; Bone Marrow; Carcinogenicity Tests; Female; Lymphocytes; Male; Mice; Micronucleus Tests; Mutagenicity Tests; Phosphodiesterase 4 Inhibitors; Rats; Rats, Sprague-Dawley; Thalidomide | 2021 |
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Biological Factors; Biological Products; Cardiovascular Diseases; Cohort Studies; Female; Humans; Interleukin-12; Interleukin-17; Male; Middle Aged; Thalidomide; Tumor Necrosis Factor Inhibitors | 2022 |
Application of Ultrasound in the Assessment of Oligoarticular Psoriatic Arthritis Subset: Results from Patients Treated with Apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Drug Monitoring; Female; Humans; Inflammation; Male; Middle Aged; Organ Dysfunction Scores; Organ Size; Patient Acuity; Reproducibility of Results; Severity of Illness Index; Synovial Fluid; Synovial Membrane; Thalidomide; Ultrasonography | 2021 |
Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Topics: Adult; Aged; Arthritis, Psoriatic; Cohort Studies; Etanercept; Female; France; Humans; Inflammatory Bowel Diseases; Interleukin-17; Male; Middle Aged; Psoriasis; Risk Assessment; Spondylitis, Ankylosing; Thalidomide | 2022 |
Systematic thermodynamic analysis of apremilast polymorphs via solubility measurement with modeling: Mechanism evaluation through molecular simulation.
Topics: Calorimetry, Differential Scanning; Solubility; Solvents; Thalidomide; Thermodynamics | 2021 |
Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single-centre pilot study.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Pilot Projects; Prospective Studies; Thalidomide | 2021 |
Apremilast ameliorates IL-1α-induced dysfunction in epidermal stem cells.
Topics: Animals; Animals, Newborn; Blotting, Western; Epithelial Cells; Inflammation; Interleukin-1alpha; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Stem Cells; Thalidomide; Tumor Necrosis Factor-alpha | 2021 |
Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: A prospective cohort study.
Topics: Adult; Humans; Nail Diseases; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome; Ultrasonography | 2021 |
Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Japan; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Use of Apremilast® in the psoriasis treatment: a real-life multicenter Italian experience.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide | 2022 |
Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis.
Topics: Animals; B-Lymphocytes, Regulatory; Disease Models, Animal; Down-Regulation; Female; Humans; Imiquimod; Interleukin-17; Mice; Psoriasis; Spleen; T-Lymphocytes, Regulatory; Thalidomide | 2021 |
When the low may still be high: the heavy burden of residual psoriasis in difficult-to-treat areas despite a low DLQI score among patients under biologics or apremilast: a 5-year, prospective, case-control study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Case-Control Studies; Humans; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
SARS-CoV-2 serology in patients on biological therapy or apremilast for psoriasis: a study of 93 patients in the Italian red zone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Therapy; COVID-19; Humans; Psoriasis; SARS-CoV-2; Severity of Illness Index; Thalidomide | 2022 |
Apremilast mitigates interleukin (IL)-13-induced inflammatory response and mucin production in human nasal epithelial cells (hNECs).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Humans; Inflammation; Interleukin-13; Mucins; Nasal Mucosa; NF-kappa B; Signal Transduction; Thalidomide | 2021 |
Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; COVID-19; Humans; Incidence; Prognosis; Psoriasis; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Thalidomide | 2022 |
Apremilast effectively inhibits TNFα-induced vascular inflammation in human endothelial cells.
Topics: Cells, Cultured; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Thalidomide; Tumor Necrosis Factor-alpha | 2022 |
Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
Topics: Adult; Arthritis, Psoriatic; Humans; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Apremilast in combination with botulinum toxin-A injection for recalcitrant Hailey-Hailey disease.
Topics: Botulinum Toxins, Type A; Humans; Pemphigus, Benign Familial; Thalidomide | 2022 |
Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Drug Therapy, Combination; Female; Humans; Interleukin-12; Interleukin-23; Male; Medication Adherence; Middle Aged; Psoriasis; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2021 |
Modification of Apremilast from Pills to Aerosol a Future Concept.
Topics: Administration, Inhalation; Aerosols; Humans; Nebulizers and Vaporizers; Particle Size; Pulmonary Disease, Chronic Obstructive; Thalidomide | 2021 |
A case of erythrodermic psoriasis successfully treated with apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Severity of Illness Index; Thalidomide | 2022 |
Successful Treatment of Palmoplantar Pustulosis With Apremilast.
Topics: Acute Disease; Humans; Psoriasis; Skin Diseases, Vesiculobullous; Thalidomide | 2021 |
Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort.
Topics: Antirheumatic Agents; Biological Factors; Biological Products; Female; Humans; Middle Aged; Psoriasis; Thalidomide | 2022 |
Successful treatment of psoriasis vulgaris with apremilast in a patient with decompensated cirrhosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Liver Cirrhosis; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide | 2022 |
Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
Topics: Animals; Drug Evaluation, Preclinical; Humans; Immunity, Innate; Inflammasomes; Interleukin-1beta; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide | 2021 |
Successful treatment of erythema nodosum leprosum with apremilast.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Panniculitis; Thalidomide | 2022 |
Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Insulin Resistance; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Humans; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Belgium; Humans; Prospective Studies; Quality of Life; Thalidomide; Treatment Outcome | 2022 |
Comparative Chiral Separation of Thalidomide Class of Drugs Using Polysaccharide-Type Stationary Phases with Emphasis on Elution Order and Hysteresis in Polar Organic Mode.
Topics: Chemical Fractionation; Molecular Structure; Organic Chemistry Phenomena; Polysaccharides; Spectrum Analysis; Thalidomide | 2021 |
How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast).
Topics: Decision Making; Dermatologists; Humans; Psoriasis; Qualitative Research; Referral and Consultation; Thalidomide | 2022 |
This Month in JAAD Case Reports: April 2022: Apremilast for Morphea.
Topics: Fibrosis; Humans; Scleroderma, Localized; Thalidomide | 2022 |
Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor.
Topics: Delayed-Action Preparations; Drug Liberation; Phosphodiesterase 4 Inhibitors; Solubility; Thalidomide | 2022 |
Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Chronic Disease; Humans; Neoplasms; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Determinants of patient and physician treatment satisfaction in moderate-to-severe psoriasis: a multinational survey of psoriasis patients.
Topics: Adult; Biological Products; Cross-Sectional Studies; Dermatologists; Female; France; Germany; Humans; Immunosuppressive Agents; Italy; Logistic Models; Male; Middle Aged; Patient Satisfaction; Personal Satisfaction; Psoriasis; Quality of Life; Severity of Illness Index; Spain; Surveys and Questionnaires; Thalidomide; Treatment Outcome; United Kingdom; United States | 2021 |
Apremilast in oral lichen planus - a multicentric, retrospective study.
Topics: Humans; Lichen Planus, Oral; Retrospective Studies; Thalidomide | 2022 |
[Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases].
Topics: Behcet Syndrome; Humans; Quality of Life; Stomatitis, Aphthous; Thalidomide | 2022 |
The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Cardiovascular Diseases; Cross-Sectional Studies; Humans; Leukocytes, Mononuclear; Methotrexate; Thalidomide | 2022 |
Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?
Topics: Acrodermatitis; Exanthema; Humans; Psoriasis; Skin Diseases, Vesiculobullous; Thalidomide | 2022 |
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cohort Studies; Humans; Psoriasis; Thalidomide | 2022 |
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cohort Studies; Humans; Psoriasis; Thalidomide | 2022 |
The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Pilot Projects; Psoriasis; Thalidomide; Treatment Outcome | 2022 |
A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece - the 'APRAISAL' study.
Topics: Adult; Greece; Humans; Middle Aged; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use.
Topics: Biological Products; Humans; Methotrexate; Psoriasis; Retrospective Studies; Thalidomide | 2022 |
Expert recommendations for the use of apremilast in psoriatic arthritis.
Topics: Algorithms; Arthritis, Psoriatic; Humans; Spain; Thalidomide | 2023 |
Effects of Apremilast on Induced Hypertrophic Scar of Rabbits.
Topics: Animals; Cicatrix, Hypertrophic; Collagen; Male; Rabbits; Skin; Thalidomide | 2021 |
Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: A long-term experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Mental health, insomnia and suicidal ideation during treatment with apremilast.
Topics: Humans; Mental Health; Risk Factors; Sleep Initiation and Maintenance Disorders; Suicidal Ideation; Thalidomide | 2022 |
Self-Nanoemulsifying Drug Delivery System (SNEDDS) of Apremilast: In Vitro Evaluation and Pharmacokinetics Studies.
Topics: Drug Delivery Systems; Emulsions; Nanoparticles; Particle Size; Renal Dialysis; Thalidomide | 2022 |
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; HIV Infections; Humans; Thalidomide; Treatment Outcome | 2022 |
Nanocrystal-based gel of apremilast ameliorates imiquimod-induced psoriasis by suppressing inflammatory responses.
Topics: Animals; Disease Models, Animal; Gels; Imiquimod; Nanoparticles; Psoriasis; Skin; Thalidomide | 2022 |
Apremilast Use in Oligoarticular Psoriatic Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Psoriasis; Thalidomide | 2022 |
Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
Topics: Behcet Syndrome; Cytokines; Humans; Interferon-gamma; Interleukin-10; Interleukin-23; Interleukin-6; Interleukin-8; Oral Ulcer; Thalidomide; Tumor Necrosis Factor-alpha | 2022 |
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cohort Studies; Humans; Psoriasis; Thalidomide | 2022 |
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cohort Studies; Humans; Psoriasis; Thalidomide | 2022 |
Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Psoriasis; Thalidomide | 2022 |
Apremilast: A novel adjuvant treatment for refractory isotretinoin-induced acne fulminans.
Topics: Acne Vulgaris; Adjuvants, Immunologic; Humans; Isotretinoin; Thalidomide | 2022 |
Protective roles of apremilast via Sirtuin 1 in atherosclerosis.
Topics: Atherosclerosis; Cholesterol; Humans; Scavenger Receptors, Class E; Sirtuin 1; Thalidomide | 2022 |
Altered platelet functions during treatment with apremilast for psoriatic arthritis: A case report.
Topics: Arthritis, Psoriatic; Humans; Thalidomide; Treatment Outcome | 2022 |
Apremilast retention rate in clinical practice: observations from an Italian multi-center study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Humans; Male; Retrospective Studies; Thalidomide; Treatment Outcome | 2022 |
Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast.
Topics: Antibodies, Monoclonal, Humanized; Crohn Disease; Hidradenitis Suppurativa; Humans; Thalidomide | 2022 |
Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Claudin-5; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Endothelial Cells; Glucose; Infarction, Middle Cerebral Artery; Ischemic Stroke; Mice; Oxygen; rho-Associated Kinases; Stroke; Thalidomide | 2022 |
Effectiveness of apremilast against Behçet's disease-associated mucocutaneous and joint involvement confirmed through switching from adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Humans; Thalidomide | 2022 |
Apremilast and biologics: Characteristics of patients treated with apremilast before, during, or after a biological treatment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Humans; Psoriasis; Thalidomide | 2022 |
Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cohort Studies; Humans; Psoriasis; Thalidomide; United Kingdom | 2022 |
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Humans; Psoriasis; Thalidomide | 2023 |
Real-world experience on the efficacy and safety of apremilast in bio-naïve patients with moderate plaque psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2022 |
Targeting the Maladaptive Effects of Binge Drinking on Circadian Gene Expression.
Topics: Animals; Binge Drinking; Casein Kinases; Circadian Rhythm; Ethanol; Gene Expression; Mice; Mice, Inbred C57BL; Phosphoric Diester Hydrolases; Thalidomide | 2022 |
Psoriasis Flare in a Liver Transplant Patient: A Case Report of a Successful Treatment With Apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Liver Transplantation; Psoriasis; Severity of Illness Index; Thalidomide | 2023 |
Apremilast for the Treatment of Concomitant Subacute Cutaneous Lupus Erythematosus and Psoriasis.
Topics: Humans; Lupus Erythematosus, Cutaneous; Psoriasis; Thalidomide | 2022 |
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide | 2023 |
Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
Topics: Humans; Janus Kinase Inhibitors; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; TYK2 Kinase | 2022 |
Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment.
Topics: Humans; Interleukins; Psoriasis; Skin; Thalidomide | 2023 |
Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis.
Topics: Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Double-Blind Method; Humans; Severity of Illness Index; Thalidomide; Treatment Outcome | 2023 |
Everolimus-induced aphthous stomatitis controlled by apremilast in a heart-transplant patient.
Topics: Antineoplastic Agents; Everolimus; Humans; Stomatitis; Stomatitis, Aphthous; Thalidomide | 2023 |
Rapid and sustained response to apremilast in a patient with long-standing acrodermatitis continua of Hallopeau.
Topics: Acrodermatitis; Exanthema; Humans; Psoriasis; Thalidomide | 2022 |
Efficacy and safety of apremilast in a patient with paraneoplastic dermatomyositis with resistant skin disease.
Topics: Dermatomyositis; Humans; Patients; Thalidomide | 2023 |
Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Psoriasis; Quality of Life; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2023 |
Subcorneal pustular dermatosis treated successfully with apremilast.
Topics: Humans; Skin; Skin Diseases, Vesiculobullous; Thalidomide | 2023 |
Apremilast for the treatment of papuloerythroderma of Ofuji.
Topics: Dermatitis, Exfoliative; Humans; Skin Diseases, Papulosquamous; Thalidomide | 2023 |
Comparison of risankizumab with apremilast for the treatment of moderate psoriasis.
Topics: Antibodies, Monoclonal; Double-Blind Method; Humans; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2023 |